

## **CURRICULUM VITAE**

**Irene Oi-Lin NG**

P. 2 - 3	General Information
P. 4 - 23	Research Outputs / Publications
P. 24	Editorship or Editorial Committee Membership of Scholarly Journals
P. 25 - 29	Invited Lectures and Presentations
P. 30 - 31	International Standing and Contributions to Knowledge in the Field
P. 32 - 35	Research Grants
P. 36 – 40	Teaching and Examinership
P. 41	Professional Standing
P. 42 - 43	Administration and Clinical Services

**CURRICULUM VITAE**  
**Irene Oi-Lin NG, MD, PhD**

Loke Yew Professor in Pathology and Chair Professor in Pathology  
Department of Pathology, The University of Hong Kong

Head,  
Department of Pathology, The University of Hong Kong

Director,  
State Key Laboratory for Liver Research (University of Hong Kong)

**PERSONAL PARTICULARS**

Place of Birth: Hong Kong  
Address: Room 127B, University Pathology Building, Department of Pathology, Queen Mary  
Hospital, Pokfulam, Hong Kong  
Telephone: (852) 2255-3967 or (852) 2255-4197  
Fax: (852) 2872-5197  
E-mail: iolng@hku.hk  
Personal webpage: <http://www.hku.hk/patho/staff/list/ing.html>

**EDUCATION**

1973 - 75 King's College, Hong Kong  
1980 Bachelor of Medicine & Bachelor of Surgery, The University of Hong Kong  
1994 Doctor of Medicine, The University of Hong Kong (HKU)  
2005 Doctor of Philosophy, HKU

**MEDICAL QUALIFICATION**

1980 Bachelor of Medicine & Bachelor of Surgery, HKU (MBBS)  
1986 Member of the Royal College of Pathologists (U.K.) (MRCP)  
1993 Founder Fellow of the Hong Kong College of Pathologists (FHKCPath)  
1993 Fellow of the Hong Kong Academy of Medicine (FHKAM)  
1994 Doctor of Medicine, The University of Hong Kong (MD)  
1997 Fellow of the Royal College of Pathologists (U.K.) (FRCPath)  
1998 Registered Specialist in Pathology, Hong Kong Medical Council

**EMPLOYMENTS & POSITIONS**

At Department of Pathology, The University of Hong Kong:

1981 - 1986 Clinical Pathologist  
1986 - 1992 Lecturer  
1992 - 1996 Senior Clinical Pathologist (Consultant Pathologist)  
1996 - 2003 Associate Professor  
2003 - 2009 Clinical Professor  
2009 - Present Chair Professor  
2008 - Present Loke Yew Professor in Pathology

**HONORARY APPOINTMENTS**

1984 Honorary Senior Registrar, Fazakerley Hospital, Liverpool, England  
1989 Honorary Research Fellow, The Royal Free Hospital, London, England  
1989 & 1992 Honorary Research Fellow, Institute of Liver Diseases, King's College School of  
Medicine and Dentistry, London, England

1997	Visiting scholar, Department of Oral Pathology, University of California, San Francisco
1997	Visiting Professor, Shanghai Cancer Institute, China
1996 - Present	Honorary Consultant, Queen Mary Hospital, Hospital Authority, Hong Kong
2010	Visiting Professor, Shandong University, China

#### **AWARDS AND SCHOLARSHIPS**

1998 and 2008	Mrs. Gordon Wu Exchange Professorship, The University of Hong Kong
2004 and 2012	Croucher Senior Medical Research Fellowship by Croucher Foundation Hong Kong; a prestigious award to distinguished scientists in Hong Kong; first to receive the award for the second time
2005	Outstanding Research Award 2004-2005, HKU
2008 -	Loke Yew Professorship in Pathology, HKU
2009	Outstanding Research Student Supervisor Award 2007-2008, HKU
2010 -	Director, State Key Laboratory for Liver Research (Ministry of Science and Technology of China)
2012	Faculty Outstanding Research Output Award
2012 - 2017	Director, Croucher Summer Course in Cancer Biology, from Croucher Foundation

*(I have been nominated to be Member of the Chinese Academy of Engineering in April 2013.  
I have also been nominated for the State Natural Science Award in January 2013)*

#### **MEMBERSHIPS OF PROFESSIONAL SOCIETIES**

##### **International Professional Societies**

The Royal College of Pathologists  
 American Association for Cancer Research  
 American Association for the Study of Liver Disease  
 International Liver Cancer Association  
 International Association for Study of the Liver  
 International Academy of Pathology

##### **Local Professional Societies**

The Hong Kong College of Pathologists  
 (Council Member 2004 – 2008)  
 The Hong Kong Academy of Medicine  
 Hong Kong Pathology Society  
 (President 1992 – 93)  
 (Council Member 1993 - 1995)  
 Hong Kong Association for the Study of Liver Disease  
 Hong Kong Gastroenterology Society  
 Hong Kong Society of Transplantation

##### **International Study Group (By invitation)**

Laennec Society on Liver Pathology (an International liver pathology group with members from 10 countries)  
 International Cooperative Study Group on Hepatocellular Carcinoma (The University of Texas M.D. Anderson Cancer Center, Mayo Clinic, Hôpital Beaujon, Paris, and University of Hong Kong Medical Center)

## 1. RESEARCH OUTPUT / PUBLICATIONS

My current research focuses mainly on the molecular pathogenesis of liver cancer and hepatitis. Liver cancer is a major malignancy worldwide and is the second commonest fatal cancer in Hong Kong, Mainland China and Southeast Asia, as a result of the prevalent hepatitis B viral infection. My research team and I are delineating the molecular and cellular mechanisms underlying the pathogenesis of this cancer. We aim to identify important tumor suppressor and oncogenes, characterize these novel genes and molecular targets both genetically and functionally, and understand how aberrant cell signaling drives liver tumorigenesis.

### Publications

- A total of 336 publications: 2 doctorate theses, 9 book chapters, and 325 articles in journals (excluding conference papers).
- Top 1% of most cited scientists in ‘Clinical Medicine’ and ‘All Fields’ of ISI Essential Science Indicators. Total number of citations: 10649 (ISI Web of Knowledge) / 12652 (Scopus); Citations per paper: 33.7 (2013 Dec); H-index = 58 (ISI Web of Knowledge, 2013 Dec) / 60 (Scopus, 2013 Dec).

### Doctorate theses

- Doctor of Medicine (MD)      Pathobiological prognostic indicators in hepatocellular carcinoma (1994)
- Doctor of Philosophy (PhD)      Allelic and molecular changes in multistep process of hepatocarcinogenesis (2005)

### Book Chapters

1. **Ng IOL**. Primary liver tumours. In Topics in Pathology of Hong Kong, Ho F, Wu PC (Eds), University Press, 1995; pp. 101-114.
2. Fan ST, Lo CM, Cheung ST, Lai CL, **Ng IOL**. Lamivudine in liver transplantation. In: Hepatitis B in the Asian-Pacific region, Zuckermann A (Ed), Royal College of Physicians of London, 1999; pp 75-80.
3. **Ng IOL**, Qin LF, Liang ZD, Lee TKW, Chan CKL, Fan ST, Cao L, Ng M. Molecular pathology of hepatocellular carcinoma in Hong Kong. In: Molecular Genetic Basis of Cancer, Lung ML and Hsiao W (Ed), Hong Kong University of Science and Technology, 2001; pp 83-93.
4. Yam JWP, Wong CM, **Ng IOL**. Deleted in liver cancer 1 (DLC1). In: Encyclopedia of Cancer, M Schwab, 2009; pp 878-880, 2nd Edition, Springer.
5. TKW Lee, Castilho A, Ma S, **Ng IOL**. Epithelial-mesenchymal transition in cancer stem cell. In: Cancer Stem Cells, Guan XY, 2010; pp 131-143, Transworld Research Network.
6. Wong CM, Yam JWP, **Ng IOL**. Molecular pathogenesis of hepatocellular carcinoma. In: Molecular Genetics of Liver Neoplasia, Wang XW, Grisham JW & Thorgeirsson SS, 2010; pp 373-396.
7. Alan I, Dawson L, Imai R, Krishnam S, **Ng IO**, Salminen E, Seong J, Stevens G. Trends and practices in diagnosis and treatment of hepatocellular carcinoma. In IAEA Human Health Series. No. 10, International Atomic Energy Agency, United Nations; 2010.
8. Wong CM & **Ng IOL**. Genomics of hepatocellular carcinoma. In: Primary Liver Cancer – Challenges and perspectives, Gu JR. 2012; pp 45-63, Springer.
9. Au SL, **Ng IO**, Wong CM. Regulation of EZH2 and its targeted microRNAs. In: Epigenetics and Cancer, Sarkar FH. 2013; pp 33-62, Springer.

### **Full publications**

#### Journal articles

*(Irene O.L. Lui is the maiden name of Irene O.L. Ng)*

1. Kung ITM, **Lui IOL**, Loke SL, Aung Khin M, Mok CK, Lam WK, So SY. Pulmonary scar cancer - a pathologic reappraisal. Am J Surg Pathol 1985; 9: 391-400. (impact factor IF = 4.144)
2. **Lui IOL**, Kung ITM, Lee JMH, Boey JH. Primary colorectal signet-ring cell carcinoma in young patients: report of 3 cases. Pathology 1985; 17: 31-35. (IF = 1.643)
3. **Lui IOL**, Taylor W, Chin SH. Giant cell arteritis of the uterus and adnexa - case report. Brit J Obst Gynaecol 1985; 92:1064-1066.
4. Ho J, **Lui I**, Hui WM, Ng MMT, Lam SK. A study on the correlation of duodenal ulcer healing with campylobacter-like organisms. J Gastroenterol Hepatol 1986; 1: 69-74. (IF = 1.785)
5. Hui WM, Lam SK, Ho J, Ng M, **Lui I**, Lai CL, Lok A, Lau WY, Poon KP, Choi S, Choi TK. Chronic antral gastritis in duodenal ulcer - natural history and treatment with prostaglandin E. Gastroenterology 1986; 91: 1095-1101. (IF = 12.457)
6. Hui WM, Lam SK, Chau PY, Ho J, **Lui I**, Lai CL, Lok ASF, Ng MMT. Persistence of Campylobacter pyloridis despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. Dig Dis Sci 1987; 32: 1255-1260. (IF = 1.448)
7. Hui WM, Lam SK, Chau PY, Ho J, Lau WY, Poon KP, Lai CL, Lok ASF, **Lui IOL**, Ng M. Pathogenetic role of Campylobacter pyloridis in gastric ulcer. J Gastroenterol Hepatol 1987; 2: 309-316. (IF = 1.785)
8. **Ng IOL**, Ho J, Ng M. Intestinal metaplasia and gastric carcinoma: a histological study of 198 gastrectomy specimens. J Gastroenterol Hepatol 1988; 3:2 39-245. (IF = 1.785)
9. Lok ASF, **Ng IOL**. Prochlorperazine induced chronic cholestasis. J Hepatol 1988; 6: 369-373. (IF = 6.073)
10. Ho J, Hui WM, **Ng I**, Lam SK. Natural history of campylobacter pylori in duodenal ulcer treated with an H2-antagonist. Aliment Pharmacol Therap 1989; 3315-332. (IF = 3.287)
11. Hui WM, Lam SK, Ho J, **Ng I**, Lau WY, Branicki FJ, Lai CL, Lok ASF, Ng MMT. Effect of sucralfate and cimetidine on duodenal ulcer-associated antral gastritis and campylobacter pylori. Am J Med 1989; 86: 60-65. (IF = 4.518)
12. **Ng IOL**, Fan ST, Nicholls J. Lymphangioma of pancreas. J Gastroenterol Hepatol 1989; 4: 299-302. (IF = 1.785)
13. **Ng IOL**, Ng M, Lai ECS, Wu PC. Endoplasmic storage disease of liver: intracytoplasmic hyaline inclusions and ground glass hepatocytes. An immune light and electron microscopic characterization. Histopathology 1989; 15: 473-481. (IF = 3.216)
14. Fan ST, **Ng IOL**, Lai ECS, Choi TK. Tuberculosis of common bile duct. Am J Gastroenterol 1989; 84: 413-414. (IF = 5.608)
15. Tam AYC, **Ng IOL**, Cheung PT, Tang TS, Li CH. Haemorrhagic shock encephalopathy. Acta Paed Scand 1989; 78: 458-462. (IF = 1.297)
16. Chan KW, **Lui I**, Chung WB. Marking planes of surgical excision on specimens with mixture of India ink and acetone. J Clin Pathol 1989; 42: 893. (IF = 2.245)
17. Kwong YL, **Ng IOL**, Leung SY. Osteolytic skeletal lesion in chronic granulocytic leukemia. Pathology 1990;22: 124-125. (IF = 1.634)
18. **Ng IOL**, Leung CY, Ho JWC. Fine needle aspiration cytology diagnosis of symptomatic bony metastasis from occult hepatocellular carcinoma - a case report. Diag Cytopathol 1990; 6: 127-129. (IF = 0.786)
19. **Ng IOL**, Sturgess RP, Williams R, Portmann B. Ground glass hepatocytes with 'Lafora-like' inclusions - histochemical, immunoperoxidase and electron microscopic characterization. Histopathology 1990;17: 109-115. (IF = 3.216)
20. Lai ECS, **Ng IOL**, Ng MMT, Lok ASF, Tam PC, Fan ST, Choi TK, Wong J. Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. Hepatology 1990; 11:815-818. (IF = 10.446)

21. Lai ECS, **Ng IOL**, You KT, Tan ESY, Wong J. Hepatectomy for large hepatocellular carcinoma: the optimal resection margin. World J Surg 1991;15: 141-145. (IF = 1.765)
22. Lai ECS, **Ng IOL**, You KT, Fan ST, Mok FPT, Tan ESY, Wong J. Hepatic resection for small hepatocellular carcinoma: the Queen Mary Hospital experience. World J Surg 1991;15: 654-659. (IF = 1.765)
23. **Ng IOL**. Hepatitis - a pathological update. J Hong Kong Med Assoc 1991; 43: 26-30.
24. **Ng IOL**, Burroughs AK, Rolles K, Belli L, Scheuer PJ. Hepatocellular ballooning after liver transplantation: a light and electron microscopic study with clinicopathological correlation. Histopathology 1991; 18:323-330. (IF = 3.216)
25. Yuen ST, **Ng IOL**, Ho J, Ma L. Mesocolic lymphangioma - a case report with immunohistochemical and electron microscopic studies. Pathology 1992; 24: 221-223. (IF = 1.634)
26. Cheung ANY, Khoo Us, **Ng IOL**. Gastric carcinoma in young Hong Kong Chinese. J Gastroenterol Hepatol 1992; 7: 343-346. (IF = 1.785)
27. **Ng IOL**, Lai ECS. Hepatocellular carcinoma with an unusual papillary vesicular appearance. J Gastroenterol Hepatol 1992; 7:232-234. (IF = 1.785)
28. **Ng IOL**, Lai ECS, Ng M, Fan ST. Encapsulation in hepatocellular carcinoma - a pathologic study of 189 cases. Cancer 1992; 70:45-49. (IF = 4.43)
29. **Ng IOL**, Luk ISC, Yuen ST, Lau WK, Pritchett CJ, Ng M, Poon GP, Ho J. Surgical lateral clearance in resected rectal carcinomas - a multivariate analysis of clinicopathological features. Cancer 1993; 71: 1972-1976. (IF = 4.43)
30. Shek TWH, **Ng IOL**, Chan KW. Inflammatory pseudotumour of the liver - a report of 4 cases and review of literature. Am J Surg Pathol 1993; 17:231-238. (IF = 4.144)
31. Chu KM, Lai ECS, **Ng IOL**. Hereditary hemorrhagic telangiectasia involving the ampulla of Vater presented with recurrent gastrointestinal bleeding. Am J Gastroenterol 1993; 88: 1116-1119. (IF = 5.608)
32. Cheung ANY, **Ng IOL**. Cytomegalovirus infection of the gastrointestinal tract in non-AIDS patients. Am J Gastroenterol 1993; 88:1882-1886. (IF = 5.608)
33. **Ng IOL**, Ng M. Colonic malacoplakia - unusual association with ulcerative colitis. J Gastroenterol Hepatol 1993; 8: 110-115. (IF = 1.785)
34. **Ng IOL**, Ho J, Pritchett CJ, Chan EYT, Coleman S, Ho FCS. Use of CEA tissue staining in colorectal cancer patients - correlation with plasma CEA, histology and staging. Pathology 1993; 25: 219-222. (IF = 1.634)
35. Tsui WMS, **Ng IOL**, Colombari R, Pea M. Hepatic angiomyolipoma. Histopathology 1993; 22: 602-603. (IF = 3.216)
36. Lai ECS, You KT, **Ng IOL**, Shek TWH. The pathological basis of resection margin for hepatocellular carcinoma. World J Surg 1993; 17: 786-791. (IF = 1.765)
37. Chan TM, Lok ASF, Cheng IKP, **Ng IOL**. Chronic hepatitis C after renal transplantation: treatment with interferon-alpha. Transplantation 1993; 56: 1095-1098. (IF = 3.972)
38. Khoo US, Nicholls JM, Lee J, Saing H, **Ng IOL**. Cholestatic liver cell adenoma in a child with hirsutism and elevated serum levels of ACTH and cortisol. Histopathology 1994; 25: 586-588. (IF = 3.216)
39. Campbell F, Appleton MAC, Fuller CE, Greeff M, Hallgrimsson J, Katoh R, **Ng IOL**, Satir A, Williams GT, Williams ED. Racial variation in the O-acetylation phenotype of human colonic mucosa. J Pathol 1994; 174: 169-174. (IF = 6.21)
40. **Ng IOL**, Chung LP, Tsang S, Lam CL, Lai ECS, Fan ST, Ng M. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 1994; 9:985-990. (IF = 6.582)
41. **Ng IOL**, Lai ECS, Ho JCW, Cheung LKN, Ng MMT, So MKP. Flow cytometric analysis of DNA ploidy in hepatocellular carcinoma. Am J Clin Pathol 1994; 102:80-86. (IF = 2.939)

42. **Ng IOL**, Lai ECS, Fan ST, Ng M, Chan ASY, So MKP. Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in hepatocellular carcinoma. Cancer 1994; 73: 2268-2274. (IF = 4.43)
43. **Ng IOL**, Srivastava G, Chung LP, Tsang S, Ng M. Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese People. Cancer 1994; 74:30-37. (IF = 4.43)
44. **Ng IOL**, Ng M, Lai ECS, Fan ST. Better survival in female patients with hepatocellular carcinoma - possible causes from a pathologic approach. (IF = 4.02) Cancer 1995; 75:18-22. (IF = 4.43)
45. **Ng IOL**, Na J, Lai ECS, Fan ST, Ng M. Expression of Ki-67 antigen in hepatocellular carcinoma using monoclonal antibody MIB1 - a comparison with proliferating cell nuclear antigen. Am J Clin Pathol 1995; 104:313-318. (IF = 2.939)
46. Ng WK, Lam KY, **Ng IOL**. Langerhans' cell histiocytosis: possible association with malignant germ cell tumour. J Clin Pathol 1995; 48: 963-965. (IF = 2.245)
47. Fan ST, Lai ECS, Lo CM, **Ng IOL**, Wong J. Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg 1995;130: 198- 203. (IF = 3.058)
48. Chan ASY, Cheung KN, Chiu KY, **Ng IOL**. Effect of fixation on the demonstration of p53 oncoprotein in paraffin-embedded sections. J Hong Kong Med Technol Assoc 1995; 6: 31-36.
49. Peh W, Ngan H, Fan ST, **Ng IOL**. Variable imaging appearances of angiomyolipomas of the liver. Brit J Radiol 1995; 68: 540-544. (IF = 1.279)
50. **Ng IOL**, Lai ECS, Chan ASY, So MKP. p53 gene overexpression in hepatocellular carcinomas in Hong Kong Chinese - a clinicopathological and prognostic correlation. J Gastroenterol Hepatol 1995; 10:250-255. (IF = 1.26)
51. **Ng IOL**, Lai ECS, Fan ST, Ng MMT, So MKP. Prognostic significance of pathologic features of hepatocellular carcinoma - a multivariate analysis of 278 patients. Cancer 1995; 76:2443-2448. (IF = 4.43)
52. **Ng IOL**. Pathological features and pathological prognostic indicators in hepatocellular carcinoma. Dig Surg 1995; 12: 16-21. (IF = 1.397)
53. Wang YN, To J, **Ng IOL**, Fan ST. A modified method of auxiliary partial liver transplantation in the rat. Hepatogastroenterology 1996; 28:2390-2392. (IF = 1.10)
54. **Ng IOL**, Lai KC, Ng M. Clinical and histologic features of gastric antral vascular ectasia - successful treatment with endoscopic laser therapy. J Gastroenterol Hepatol 1996; 11: 270-274. (IF = 1.26)
55. Chan KL, Saing H, Fan ST, Wei W, **Ng IOL**, Tsoi NS. Cyclosporin A based immunotherapy for paediatric liver transplantation in Hong Kong. Transplant Proc 1996; 28:1302-1303. (IF = 0.85)
56. Ng WK, Collins RJ, Shek WH, **Ng IOL**. Cytologic diagnosis of carcinoma showing thymoma-like element 'CASTLE' of thyroid gland: report of a case with histologic correlation. Diag Cytopathol 1996; 15: 224-227. (IF = 1.03)
57. Ng WK, **Ng IOL**. Focal fatty change - a rare hepatic manifestation of diabetes mellitus. Hong Kong Med J 1996; 2:99-101.
58. Shek WH, Ho F, **Ng IOL**, Chan ACL, Srivastava G, Ma L. Follicular dendritic cell tumor of liver - Evidence for an Epstein-Barr virus-related clonal proliferation of follicular dendritic cells. Am J Surg Pathol 1996; 20:313-324. (IF = 3.70)
59. Fan ST, Lo CM, Chan KL, Lo R, Saing H, Wei W, Lai CL, Tsoi NS, **Ng IOL**, Chan JKF, Chau MT, Tso WK, Wong J. Liver transplantation - perspective from Hong Kong. Hepatogastroenterology 1996; 43: 893-897. (IF = 1.10)
60. Fan ST, Lo CM, Man K, Chan KL, Saing H, Wei WI, Lo JW, Lai CL, Choi NS, **Ng IOL**, Chau MT, Chan KF, Wong J. Liver transplantation: a report of 23 cases. Chin Med J 1996; 76:267-270. (IF = 0.12)

61. Shek WH, Luk ISC, **Ng IOL**, Lo CY. Lymphoepithelioma-like carcinoma of the thyroid gland: lack of evidence of association with Epstein-Barr virus. Hum Pathol 1996; 27: 851-853. (IF = 3.66)
62. **Ng IOL**, Ng M, Lai ECS, Fan ST. Pathological features and patient survival in hepatocellular carcinoma in relation to age. J Surg Oncol 1996; 61:134-137. (IF = 1.32)
63. Shek WH, **Ng IOL**, Chiu EKW, Chan KW. Pathology of bone marrow transplantation in Hong Kong Chinese. Hong Kong Med J 1996; 2: 133-137.
64. **Ng IOL**. Pathological prognostic factors in hepatocellular carcinoma. (Invited review) Cancer J 1996; 9:226-228. (IF = 2.09)
65. Chan KL, Saing H, Fan ST, **Ng IOL**, Chan CF, Ha SY, Lau YL. Primary paediatric liver tumours - Queen Mary Hospital experience. Hong Kong J Paed (new series) 1996; 1:60-63.
66. Lam KY, Chan ACL, **Ng IOL**. Adrenal lipoma: a report of two cases and review of the literature. Scand J Urol Nephrol 1997; 31: 89-90. (IF = 0.72)
67. Lo CM, Fan ST, Liu CL, Wei WI, Lo RJW, Lai CL, Chan JKF, **Ng IOL**, Fung A, Wong J. Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg 1997; 226: 261-270. (IF = 6.68)
68. **Ng IOL**, Ng M, Fan ST. Better survival in women with resected hepatocellular carcinoma is not related to tumour cell proliferation nor tumour expression of estrogen and progesterone receptors. Am J Gastroenterol 1997; 92:1355-1358. (IF = 3.55)
69. Lo CM, Fan ST, Liu CL, Lo RJW, Lau GKK, Wei WI, Li JHC, **Ng IOL**, Wong J. Extending the limit on the size of adult recipient in living donor liver transplantation using extended right lobe graft. Transplantation 1997; 63:1524-1528. (IF = 4.18)
70. Fan ST, Liu BC, Lo CM, Man K, **Ng IOL**, Wong J. Liver transplantation for alcoholic cirrhosis. Chin J Gen Surg 1997; 6:1-4.
71. Saing H, Fan ST, Chan KL, Wei WI, Lo CM, Mya GH, Tsoi NS, Yuen KY, **Ng IOL**, Lo JWR, Chau MT, Tso WK, Chan J, Wong J. Liver transplantation in children: the experience of Queen Mary Hospital, Hong Kong. J Pediatr Surg 1997; 32:80-83. (IF = 1.09)
72. Fan ST, Lo CM, Lo RJW, Fung KY, Wei WI, Chen YB, Lai CL, **Ng IOL**, Yuen KY, Chan JKF, Wong J. Management of fulminant hepatic failure at Queen Mary Hospital. Chin Med J 1997; 110:482-484. (IF = 0.12)
73. Man K, Fan ST, **Ng IOL**, Lo CM, Liu CL, Wong J. Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg 1997; 226:704-713. (IF = 6.68)
74. **Ng IOL**, Shek WH, Nicholls J, Ma L. Combined hepatocellular and cholangiocarcinoma - a pathologic study. J Gastroenterol Hepatol 1998; 13:34-40. (IF = 1.26)
75. Lo CM, Fan ST, Liu CL, Lo RJ, Lai CL, Lau GK, Chan JK, **Ng IOL**, Wong J. Five-year experience with the development of a liver transplant program in Hong Kong. Transplant Proc 1998; 30:3247-3248. (IF = 0.85)
76. Peh W, Shek TWH, **Ng IOL**, Lo CM, Fan ST, Ngan H. Imaging of follicular dendritic cell tumours of the liver. J Gastroenterol Hepatol 1998; 13:1146-1151. (IF = 1.26)
77. Shek TWH, Liu CL, Peh WCG, Fan ST, **Ng IOL**. Intraabdominal follicular dendritic cell tumour: a rare tumour in need of recognition. Histopathology 1998; 33:465-470. (IF = 2.81)
78. Lau H, Fan ST, **Ng IOL**, Wong J. Long-term prognosis after hepatectomy for hepatocellular carcinoma. Cancer 1998; 83:2302-2311. (IF = 4.43)
79. **Ng IOL**. Molecular and cellular pathology of hepatocellular carcinoma. (Invited review) J Gastroenterol Hepatol 1998; 13:S299-303. (IF = 1.26)
80. Qin LF, **Ng IOL**, Fan ST, Ng M. p21, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 1998; 79:424-428. (IF = 4.23)

81. **Ng IOL**, Lam AKY, Ng M, Kwong D, Sham J. P-glycoprotein expression of the multidrug-resistance gene is induced by radiation in oral squamous cell carcinomas. Cancer 1998; 83:851-857. (IF = 4.43)
82. Chan KL, Fan ST, Saing H, Wei W, Lo CM, Tsoi NS, **Ng IOL**, Chau MT, Tsoi WK, Chan J, Yuen KY, Tam PKH, Wong J. Paediatric liver transplantation in Queen Mary Hospital experience. Chin Med J 1998; 111:610-614. (IF = 0.12)
83. Lam KY, **Ng IOL**, Chan GSW. Palatal pleomorphic adenoma with florid squamous metaplasia – a potential diagnostic pitfall. J Oral Pathol Med 1998; 27: 407-410. (IF = 1.48)
84. **Ng IOL**. Prognostic significance of pathological and biological factors in hepatocellular carcinoma. (Invited review) J Gastroenterol Hepatol 1998; 13:666-670. (IF = 1.26)
85. **Ng IOL**, Lee J, Srivastava G, Ng M. Role of insulin-like growth factor II in hepatocellular carcinoma - a study of mRNA and pathological features. J Gastroenterol Hepatol 1998; 13:152-157. (IF = 1.26)
86. Lo CM, Fan ST, Liu CL, Chan KL, **Ng IOL**, Lai CL, Lau GK, Fung SK, Wong J. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. Transplant Proc 1998; 30:3587-3588. (IF = 0.85)
87. Wang YN, **Ng IOL**, To J, Fan ST. A modified method of auxiliary partial liver transplantation in the rat. Hepatogastroenterology 1999; 46:428-431. (IF = 1.10)
88. Yang ZF, Wang WL, Lo CM, **Ng IOL**, Fan ST. Acute cellular rejection in liver transplantation. Clin J Org Transplant 1999; 20:237-239.
89. Schoelch ML, Regezi JA, Dekker NP, **Ng IOL**, McMillan A, Le AT, Silverman SJR, Fu KK. Cell cycle proteins and the development of oral squamous cell carcinoma. Eur J Cancer B - Oral Oncol 1999; 35:333-342. (IF = 1.61)
90. **Ng IOL**, Lam KY, Ng M, Regezi JA. Expression of p21/waf1 in oral squamous cell carcinomas - correlation with p53 and mdm2 genes and cellular proliferation index. Eur J Cancer B - Oral Oncol 1999; 35:63-69. (IF = 1.61)
91. Fan ST, **Ng IOL**, Poon RTP, Lo CM, Liu CL, Wong J. Hepatectomy for hepatocellular carcinoma - the surgeon's role in long-term survival. Arch Surg 1999; 134:1124-1130. (IF = 2.79)
92. Poon RTP, Fan ST, Lo CM, Liu CL, Ngan H, **Ng IOL**, Wong J. Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. Am J Gastroenterol 1999; 94:2460-2466. (IF = 3.55)
93. Tsang WM, Tong ACK, **Ng IOL**. Intraoral mucoepidermoid carcinoma - a clinicopathological study of four cases. Asian J Oral Maxillofacial Surg 1999; 11:143-148.
94. Lo CM, Fan ST, Lai CL, Liu CL, Yuen MF, **Ng IOL**, Wong J. Lamivudine prophylaxis in liver transplantation for hepatitis B in Asian. Transplant Proc 1999; 31:535-536. (IF = 0.85)
95. Saing H, Fan ST, Chan KL, Lo CM, Wei WI, Tsoi NS, Yuen KY, **Ng IOL**, Chau MT, Tso WK, Chan JK, Wong J. Liver transplantation in infants. J Pediat Surg 1999; 34:1721-1724. (IF = 1.19)
96. Regezi JA, Dekker NP, McMillan A, Ramirez-Amador V, Meneses-Garcia A, Ruiz-Godoy R, Chrysomali E, **Ng IOL**. p53, p21, Rb, MDM2 proteins in tongue carcinoma from patients <35 years vs. >75 years. Eur J Cancer B - Oral Oncol 1999; 35:379-383. (IF = 1.61)
97. Man K, Fan ST, **Ng IOL**, Lo CM, Liu CL, Wong J. Tolerance of Pringle maneuver in hepatectomy for liver tumors. Arch Surg 1999; 134:533-539. (IF = 2.79)
98. Lam KY, **Ng IOL**, Yuen APW, Kwong DLW, Wei WI. Cyclin D1 expression in oral squamous cell carcinomas: clinicopathological relevance and correlation with p53 expression. J Oral Pathol Med 2000; 29:167-172. (IF = 1.48)
99. Poon RTP, Fan ST, **Ng IOL**, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89:500-507. (IF = 4.43)

100. **Ng IOL**, Liang ZD, Cao L, TWK Lee. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines defective in DLC-1. Cancer Res 2000; 60: 6581-6584. (IF = 8.65)
101. Au WY, Ma SK, Kwong YL, **Ng IOL**, Hawkins BR, Wan TSK, Liu CL, Fan ST, Lo CM. Graft versus host disease after liver transplantation: documentation by FISH and HLA typing. Clin Transplant 2000; 14:173-176. (IF = 1.89)
102. **Ng IOL**, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma - a determinant of chemotherapy response. American Journal of Clinical Pathology 2000; 113:355-363. (IF = 3.14)
103. Poon RTP, Fan ST, Lo CM, Liu CL, **Ng IOL**, Wong J. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 2000; 18:1094-1101. (IF = 8.53)
104. Lo CM, Fan ST, Liu CL, Lai CL, Lau GK, Yong BH, **Ng IOL**, Young K, Chan JK, Wong J. Liver transplantation in Hong Kong - A wider application. Transplant Proc 2000; 32:2141. (IF = 0.85)
105. Chan KL, S T, Fan, Saing H, Wei W, Lo CM, **Ng IOL**, Tsoi NS, Chan J, Tso WK, Yuen KY, Tam PK, Wong J. Liver transplantation is not contraindicated in infancy. Transplantation Proc 2000; 32:2142-2143. (IF = 0.85)
106. **Ng IOL**, Xiao L, Lam KY, Yuen PW, Ng M. Microsatellite alterations in squamous cell carcinoma of the head and neck - clustering of loss of heterozygosity in a distinct subset. Eur J Cancer - Oral Oncol 2000; 36:484-490. (IF = 1.61)
107. **Ng IOL**, Shek WH, Thung SN, Ye M, Lo CM, Fan ST, Lee JM, Chan KW, Cheung AN. Microsatellite analysis in posttransplant lymphoproliferative disorder to determine donor/recipient origin. Mod Pathol 2000; 11:1180-1185. (IF = 3.21)
108. Chan GSW, Ng WK, **Ng IOL**, Dickens P. Massive pulmonary tumour embolism due to hepatocellular carcinoma: a diagnosis commonly missed. Forensic Sci Int 2000; 108:215-221. (IF = 1.05)
109. Lo CM, Fan ST, Liu CL, **Ng IOL**, Lam BK, Yong BH, Lai CL, Lau GK, Wong J. More effective immunosuppression with the use of FK506 after liver transplantation. Transplant Proc 2000; 32:2269-2270. (IF = 0.85)
110. **Ng IOL**, Fan ST. p53 overexpression in hepatocellular carcinoma. (Invited commentary) Arch Surg 2000; 135:1476. (IF = 2.79)
111. Chan KL, Fan ST, Saing H, Wei W, Lo CM, **Ng IOL**, Tsoi NS, Chan J, Tso WK, Yuen KY, Tam PK, Wong J. Post liver transplantation stenosis of biliary-enteric anastomoses in infancy: diagnosis and treatment. Transplant Proc 2000; 32:2233-2234. (IF = 0.85)
112. Liu CL, Fan ST, **Ng IOL**, Lo CM, Poon RTP, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors - a prospective randomized study. Am J Gastroenterol 2000; 95:218-222. (IF = 3.55)
113. Poon RTP, Fan ST, **Ng IOL**, Wong J. The significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 2000; 231:544-551. (IF = 6.68)
114. Fan ST, Lo CM, Liu CL, Yong BH, Chan JKF, **Ng IOL**. Safety of donors in live-donor liver transplantation using right lobe grafts. Arch Surg 2000; 135:336-340. (IF = 2.79)
115. Yuen MF, Chan TM, Chan OO, **Ng IOL**, Lai CL. Acute pancreatitis complicating exacerbation of chronic hepatitis B infection carries a poor prognosis. J Viral Hepatol 2001; 8:459-464. (IF = 2.40)
116. Wong CM, Fan ST, **Ng IOL**.  $\beta$ -Catenin mutation and expression in hepatocellular carcinoma - clinicopathological and prognostic significance. Cancer 2001; 92:136-145. (IF = 4.43)

117. Poon RTP, **Ng IOL**, Fan ST, Lai ECS, Lo CM, Liu CL, Wong J. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol 2001; 19:3037-3044. (IF = 8.53)
118. Qin LF, **Ng IOL**. Exogenous expression of p21<sup>WAF1/CIP1</sup> exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett 2001; 172:7-15. (IF = 1.74)
119. Qin LF, **Ng IOL**. Expression of p27<sup>KIP1</sup> and p21<sup>WAF1/CIP1</sup> in primary hepatocellular carcinoma. Hum Pathol 2001; 32:778-784. (IF = 3.03)
120. Lee TKW, Han JS, Fan ST, Liang ZD, Tian PK, Gu JR, **Ng IOL**. Gene delivery using a receptor-mediated gene transfer system targeted to hepatocellular carcinoma cells. Int J Cancer 2001; 93:393-400. (IF = 4.23)
121. Poon RTP, Fan ST, Lo CM, **Ng IOL**, Liu CL, Wong J. Improving long-term survival after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234:63-70. (IF = 6.68)
122. Lo CM, Cheung ST, Lai CL, Liu CL, **Ng IOL**, Yuen MF, Fan ST, Wong J. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233:276-281. (IF = 6.68)
123. Man K, Lo CM, **Ng IOL**, Wong YC, Qin LF, Fan ST, Wong J. Liver transplantation in rats using small-for-size grafts - A study of hemodynamic and morphological changes. Arch Surg 2001; 136:280-285. (IF = 2.79)
124. Hui CK, Yuen MF, **Ng IOL**, Tsang KWT, Fong GCY, Lai CL. Low molecular weight heparin induced liver toxicity. J Clin Pharmacol 2001; 41:1-4. (IF = 2.17)
125. **Ng IOL**, Poon RTP, Lee JMF, Tso WK, Ng M, Fan ST. Microvessel density, VEGF, its receptors Flt-1 and Flk-1/KDR in human hepatocellular carcinoma. Am J Clin Pathol 2001; 116:838-845. (IF = 3.14)
126. Chim CS, **Ng IOL**, Trendell-Smith NJ, Liang R. Primary extramedullary plasmacytoma of the conjunctiva. Leuk Lymphoma 2001; 42:831-834. (IF = 1.26)
127. Poon RTP, **Ng IOL**, Lau C, Yu WC, Fan ST, Wong J. Serum basic fibroblastic growth factor in hepatocellular carcinoma: correlation with clinicopathologic features and prognosis. Am J Surg 2001; 182:298-304. (IF = 2.13)
128. Poon RTP, **Ng IOL**, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001; 233:227-235. (IF = 6.68)
129. Li KKW, **Ng IOL**, Fan ST, Albrecht JH, Yamashita K, Poon RYC. Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver 2002; 22:259-268. (IF = 1.80)
130. Wong CM, Lee JMF, Lau TCM, Fan ST, **Ng IOL**. Clinicopathologic significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res 2002; 8:2266-2272. (IF = 6.51)
131. Lee TKW, Lau T, **Ng IOL**. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol 2002; 49:78-86. (IF = 2.17)
132. Ho DWY, Lam DK, Chen YB, To J, **Ng IOL**, Fan ST. Galactosamine-induced fulminant liver failure - observation in a porcine model. Asian J Surg 2002; 25:73-79.
133. Chen X, Cheung ST, Fan ST, So S, Barry C, Higgins J, Lai KM, Ji J, **Ng IOL**, van de Rijn M, Botstein D, Brown PO. Gene expression profiles in human liver cancers. Mol Biol Cell 2002; 13:1929-1939. (IF = 7.70)
134. Qin LF, Lee TKW, **Ng IOL**. Gene expression profiling by cDNA array in human hepatoma cell line in response to cisplatin treatment. Life Sci 2002; 14:1677-1690. (IF = 1.76)
135. Liu CL, Fan ST, Lo CM, Law WL, **Ng IOL**, Wong J. Hepatic resection for colorectal liver metastases: prospective study. Hong Kong Med J 2002; 8:329-333.

136. Chan KL, Lee MF, Guan XY, Fan ST, **Ng IOL**. High-density allelotyping on chromosome 8p in hepatocellular carcinoma and clinicopathological correlation. Cancer 2002; 94:3185-3191. (IF = 4.43)
137. **Ng IOL**, Poon RTP, Shek TWH, Fan ST. Histological activity in noncancerous livers in patients with hepatectomy for hepatocellular carcinoma - clinicopathological correlation and survival analysis. American Journal of Clinical Pathology 2002; 117:411-418. (IF = 3.14)
138. Cheung ST, Chen X, Guan XY, Wong SY, Tai LS, **Ng IOL**, So S, Fan ST. Identifying metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Research 2002; 62:4711-4721. (IF = 8.65)
139. Qin LF, **Ng IOL**. Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett 2002; 175:27-38. (IF = 1.74)
140. Liu CL, Fan ST, Lo CM, **Ng IOL**, Wong J. Intraoperative iatrogenic rupture of hepatocellular carcinoma. World J Surg 2002; 26:348-352. (IF = 1.64)
141. Man K, Liang TB, Lo CM, Liu CL, **Ng IOL**, Yu WC, Fan ST. The study of hepatic stress gene expression and ultrastructural changes under intermittent Pringle manoeuvre. Hepatobil Pancreat Dis Int 2002; 1: 249-257.
142. Saing H, Fan ST, Tam PKH, Lo CM, Wei WI, Chan KL, Tsoi NS, Yuen KY, **Ng IOL**, Chau MT, Tso WK, Wong J. Surgical complications and outcome of pediatric liver transplantation in Hong Kong. J Pediat Surg 2002; 37:1673-1677. (IF = 1.304)
143. Lo CM, Fan ST, Liu CL, Yong BH, Lai CL, Lau GKK, Wei WI, Tam PKH, **Ng IOL**, Young K, Chan JKF, Tso WK, Yuen KY, Wong J. Ten-year experience with liver transplantation at Queen Mary Hospital: retrospective study. Hong Kong Med J 2002; 8:240-244.
144. Poon RTP, **Ng IOL**, Lau C, Yu WC, Yang ZF, Fan ST, Wong J. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 2002; 20:1775-1785. (IF = 8.53)
145. Ho MKS, Lee JMF, Chan CKL, **Ng IOL**. Allelic alterations in nontumorous liver tissues and corresponding hepatocellular carcinoma from Chinese patients Hum Pathol 2003; 34:699-705. (IF = 3.05)
146. Hui CK, Yuen MF, Tso WK, **Ng IOL**, Chan AOO, Lai CL. Cholangiocarcinoma in liver cirrhosis. J Gastroenterol Hepatol 2003;18:337-341. (IF = 1.26)
147. Yuen MF, Kato T, Mizokami M, Chan AOO, Yuan HJ, Wong DKH, Sum SM, **Ng IOL**, Fan ST, Lai CL. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39:850-855. (IF = 5.283)
148. Pang A, **Ng IOL**, Fan ST, Kwong YL. Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. Cancer Genet Cytogenet 2003;146:8-15. (IF = 1.542)
149. Chan AO, Wong BCY, Lan HY, Loke SL, Chan WK, Hui MM, Yuen YH, **Ng IOL**, Hou L, Wong WM, Yuen MF, Luk JMC, Lam SK. Deregulation of cadherin-catenin complex in precancerous lesions of gastric adenocarcinoma. J Gastroenterol Hepatol 2003;18:534-539. (IF = 1.26)
150. **Ng IOL**, Guan XY, Poon RTP, Fan ST, Lee JMY. Determination of the molecular relationship between multiple tumor nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol 2003;199:345-352. (IF = 6.21)
151. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY, **Ng IOL**. DLC2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem 2003; 278:10824-10830. (IF = 7.26)
152. Man K, Lo CM, Liu CL, Zhang ZW, Lee TKW, **Ng IOL**, Fan ST, Wong J. Effects of the intermittent Pringle manoeuvre on hepatic gene expression and ultrastructure in a randomized clinical study. Br J Surg 2003;90:183-189. (IF = 3.46)

153. Au WY, Lau GKK, Lie AKW, Liang R, Lo CM, Fan ST, Liu CL, Hawkins BR, **Ng IOL**, Kwong YL. Emergency orthotopic liver transplantation for fulminant reactivation of hepatitis B (HBV) after unrelated marrow transplantation. Clin Transplant 2003; 17: 121-125. (IF = 1.90)
154. Tse E, Lie A, **Ng IOL**, Kwong YL. Fatal skin rashes and myalgia in a leukemic patient. Haematologica 2003;88:EIM02. (IF = 3.2)
155. Man K, Fan ST, Lo CM, Liu CL, Fung PCW, Liang TB, Lee TK, Tsui SH, **Ng IOL**, Zhang ZW, Wong J. Graft injury in relation to graft size in right lobe live donor liver transplantation - a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intra-graft gene expression. Ann Surg 2003; 237:256-264. (IF = 6.68)
156. Liu CL, Fan ST, Lo CM, **Ng IOL**, Poon RTP, Wong J. Hepatic resection for bilobar hepatocellular carcinoma: Is it justified? Arch Surg 2003;138:100-104. (IF = 2.63)
157. Liu CL, Fan ST, Lo CM, **Ng IOL**, Lam CM, Poon RTP, Wong J. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg2003;138:86-90. (IF = 2.79)
158. **Ng IOL**, Chan KL, Shek WH, Lee JMF, Fong DYT, Lo CM, Fan ST. High frequency of chimerism in transplanted livers. Hepatology 2003;38:989-998. (Featured on cover and with editorial comment) (IF = 9.83)
159. Man K, Lo CM, Lee TKW, **Ng IOL**, Fan ST. Intra-graft gene expression profiles by cDNA microarray in small-for-size liver grafts. Liver Transplant 2003; 9:425-432. (IF = 4.242)
160. Ren Y, Tsui HT, Poon RT, **Ng IOL**, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST. Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 2003;107:22-29. (IF = 4.375)
161. Poon RTP, Fan ST, **Ng IOL**, Wong J. Prognosis after hepatic resection for stage IVA hepatocellular carcinoma - need for reclassification. Ann Surg 2003;237:376-383. (IF = 6.68)
162. Wong WM, Hui CK, Yuen MF, Lai CL, **Ng IO**, Trendell-Smith N, Ooi GC, Fan ST. Reversal of protein-losing enteropathy by liver transplantation. (IF = 1.12) J Clin Gastroenterol 2003;36:86-87. (IF = 1.564)
163. Ma SY, Au WY, **Ng IOL**, Lie AKW, Leung AYH, Liang RHS, Lau GKK, Kwong YL. Role of liver biopsy in the management of liver dysfunction after hematopoietic stem cell transplantation in a hepatitis B virus prevalent patient population. Transplantation 2003;76:169-176. (IF = 3.608)
164. Lo CM, Fan ST, Liu CL, Yong BH, Wong Y, **Ng IOL**, Wong J. Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transplantation 2003;9:827-832. (IF = 4.242)
165. Wong W, Luk M, **Ng IOL**, Hu Y, Liu D, Fan ST. Identification of liver-intestine cadherin in hepatocellular carcinoma - a potential disease marker. Biochem Biophys Res Com 2003; 311:618-24. (IF = 2.836)
166. Lee TWK, Man K, Ling MT, Wang XH, Wong YC, Poon RTP, **Ng IOL**, Fan ST. Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. Carcinogenesis 2003; 24:1729-36. (IF = 4.663)
167. Wong CM, Ching YP, Lee JMF, Jin DY, **Ng IOL**. Genetic and epigenetic alterations on DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003; 63: 7646-7651. (IF = 8.65)
168. Chan AO, **Ng IOL**, Lam CM, Shek TW, Lai CL. Cholestatic jaundice caused by sequential carbimazole and propylthiouracil treatment. Hong Kong Med J 2003; 9:377-380.
169. Tong ACK, **Ng IOL**, Yan BSW. Variations in clinical presentations of the simple bone cyst. J Oral Maxillofacial Surg 2003, 61:1487-1491. (IF = 0.912)
170. Liu CL, Fan ST, Lo CM, Wong Y, **Ng IOL**, Lam CM, Poon RTP, Wong J. Abdominal drainage after hepatic resection is contraindicated in patients with chronic liver diseases. Ann Surg 2004; 239: 194-201. (IF = 5.907)
171. Tsang WM, Tong CK, Chow LTC, **Ng IOL**. Massive osteolysis of the maxillofacial skeleton - report of 2 cases involving the mandible. J Oral Maxillofacial Surg 2004; 62:225-30. (IF = 0.77)

172. Ooi GC, Khong PL, Chan GC, Chan KN, Chan KL, Lam W, **Ng IOL**, Ha SY. Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients. Br J Haematol 2004;124:385-390. (IF = 3.195)
173. Ng KKC, Poon RTP, Lo CM, Liu CL, Lam CM, **Ng IOL**, Fan ST. Impact of preoperative fine-needle aspiration cytology on clinical outcome of patients with hepatocellular carcinoma in a tertiary referral center. Arch Surg 2004;139:193-200. (IF = 3.076)
174. Lo CM, Cheung ST, **Ng IOL**, Liu CL, Lai CL, Fan ST. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance – successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transplant 2004;10:557-563. (IF = 3.984)
175. Lam CM, Chan AOO, Ho P, **Ng IOL**, Lo CM, Liu CL, Poon RTP, Fan ST. Differences in clinicopathological features in a cohort of 1,863 young and old patients with hepatitis B related hepatocellular carcinoma. Aliment Pharmacol Therap 2004;19:771-777. (IF = 3.981)
176. Pang R, Yuen J, Yuen MF, Lai CL, Lee TWK, Man K, Poon RTP, Fan ST, Wong CM, **Ng IOL**, Kwong YL, Tse E. PIN1 over-expression and beta-catenin gene mutations are distinct events in human hepatocarcinogenesis. Oncogene 2004; 23:4182-4186. (IF = 6.318)
177. Lee PKM, Samman N, **Ng IOL**. Unicystic ameloblastoma - use of carnoy's solution after enucleation. Int J Oral Maxillofacial Surg 2004;33:263-267. (IF = 1.106)
178. Ma SY, Au WY, **Ng IOL**, Lie AKW, Leung AYH, Liang R, Lau GKK, Kwong YL. Hepatic graft-versus-host disease after hematopoietic stem cell transplantation: clinicopathologic features and prognostic implication. Transplantation 2004; 77: 1252-1259. (IF = 3.568)
179. Liu CL, Fan ST, Lo CM, Chan SC, **Ng IOL**, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroid and reduction of tacrolimus dosage. Liver Transplant 2004; 10:728-733. (IF = 3.984)
180. Ma SY, Au WY, Lie AK, **Ng IOL**, Leung AY, Tse EW, Liang R, Lau GK, Kwong YL. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 34:57-61. (IF = 2.101)
181. Yuen MF, Wong DKH, Sablon E, Tse EWC, **Ng IOL**, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condrey LD, Lai CL. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histologic and clinical aspects. Hepatology 2004; 39:1694-1701. (IF = 10.416)
182. Lo CM, Fan ST, Liu CL, Yong BH, Wong Y, Lau GKK, Lai CL, **Ng IOL**, Wong J. Lessons learned from 100 right lobe living donor live transplants. Ann Surg 2004; 240:151-158. (IF = 5.907)
183. Lee TKW, Man K, Poon RTP, Lo CM, **Ng IOL**, Fan ST. Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma. Oncol Rep 2004;12:25-31. (IF = 1.356)
184. Chan CF, Yau TO, Jin DY, Fan ST, **Ng IOL**. Evaluation of nuclear factor- $\kappa$ B, urokinase-type plasminogen activator (uPA) and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 4140-4149. (IF = 6.51)
185. Ho JCY, Cheung ST, Leung PKL, **Ng IOL**, Fan ST. Decreased expression of cytochrome P450 2E1 is associated with poor prognosis of hepatocellular carcinoma. Int J Cancer 2004; 111:494-500. (IF = 4.416)
186. Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, **Ng IOL**, Xu RR, Fan ST. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 2004; 25:2397-2405. (IF = 5.375)
187. Poon RTP, Ho JWY, Tong CSW, Lau C, **Ng IOL**, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004; 91:1354-1360. (IF = 3.580)

188. Lai ATY, Lam CM, Ng KKC, Yeung C, Ho WL, Poon LT, **Ng IOL**. Hepatic actinomycosis presenting as a liver tumor – Case report and review of literature. Asian J Surg 2004; 27:345-347.
189. Yuen MF, **Ng IOL**, Fan ST, Yuan HJ, Wong KH, Yuen CH, Sum SM, Lai CL. Significance of HBV DNA levels in liver histology of HBeAg and anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol 2004; 99:2032-2037. (IF = 4.716)
190. Chan KL, Guan XY, **Ng IOL**. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol 2004; 35: 1324-1331. (Featured on cover and with editorial on it) (IF = 3.369)
191. Pawlik TM., Poon RT, Abdalla EK, Ikai I, Curley SA, Nagorney D, Belghiti J, **Ng IOL**, Yamaoka Y, Lauwers G, Vauthey JN. Hepatitis serology defines tumor and liver disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg 2004; 8:794-805. (IF = 2.064)
192. Liu CL, Fan ST, Lo CM, Chan SC, Tso WK, **Ng IOL**, Wong J. Hepatic resection for incidentaloma. J Gastrointest Surg 2004; 8:785-793. (IF = 2.064)
193. Sze KMF, Ching YP, Jin DY, **Ng IOL**. Association of MAD2 expression with mitotic checkpoint competence in hepatoma cells. J Biochem Sci 2004; 11:920-927. (IF = 1.67)
194. Cheung ST, Wong SY, Leung KL, Chen X, So S, **Ng IOL**, Fan ST. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. Clin Cancer Res 2004; 10:7629-7636. (IF = 5.62)
195. Yau TO, Chan CY, Chan KL, Lee MF, Wong CM, Fan ST, **Ng IOL**. HDPR1, a novel inhibitor of the WNT/ $\beta$ -catenin signaling, is frequently downregulated in hepatocellular carcinoma: Involvement of methylation-mediated gene silencing. Oncogene 2005; 24:1607-1614. (IF = 6.31)
196. Lee TKW, Man K, Ho JWY, Wang XH, Poon RTP, Sun CKW, Ng KTP, **Ng IOL**, Xu R, Fan ST. The significance of Rac signaling pathway in hepatocellular carcinoma cell motility: implication for new therapeutic target. Carcinogenesis 2005; 26: 681-687. (IF = 5.48)
197. Cheung ST, Leung KL, Ip YC, Chen X, Fong DY, **Ng IOL**, Fan ST, So S. Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin Cancer Res 2005; 11:551-556. (IF = 5.62)
198. Ho CC, Siu WY, Chow JPH, Lau A, Arooz T, Tong HY, **Ng IOL**, Poon RYC. The relative contribution of CHK1 and CHK2 to the Adriamycin-induced checkpoint. Exp Cell Res 2005; 304:1-15. (IF = 3.949)
199. Chin KT, Zhou HJ, Wong CM, Lee JMF, Chan CP, Qiang BQ, Yuan JG, **Ng IOL**, Jin DY. The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. Nucl Acid Res 2005; 33: 1859-1873. (IF = 7.26)
200. Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, **Ng IOL**, Fan ST, Poon RT. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005; 12: 364-373. (IF = 3.456)
201. Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, Kianmanesh R, **Ng IOL**, Curley SA, Yamaoka Y, Lauwers GY, Vauthey JN. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137: 403-410. (IF = 2.566)
202. Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, Nagorney DM, Belghiti J, **Ng IO**, Yamaoka Y, Lauwers GY, Vauthey JN; International Cooperative Study Group on hepatocellular carcinoma. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140: 450-457; discussion 457-458. (IF = 3.053)
203. **Ng IOL**. Chimerism in transplanted allografts. (Invited Leading Article). Br J Surg 2005; 92: 661-662. (IF = 3.74)

204. Lo CM, Liu CL, Lau GK, Chan SC, **Ng IOL**, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transplant 2005; 11: 807-813. (IF = 4.447)
205. Yuan HJ, Yuen MF, Wong DKH, Sum SM, Sablon E, **Ng IOL**, Lai CL. Impact of precore and core mutations on hepatic histology in patients with chronic hepatitis B. Aliment Pharmacol Therap 2005; 22:301-307. (IF = 3.434)
206. Yuen MF, Tanaka Y, **Ng IOL**, Mizokami M, Yuen JC, Wong DK, Yuan HJ, Sum SM, Hui CK, Chan AO, Lai CL. Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core promoter and precore mutations. J Viral Hepat 2005; 12: 513-518. (IF = 2.550)
207. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, **Ng IOL**, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplant 2005; 11: 1086-1092. (IF = 4.0)
208. Wong CM, Yam JWP, Ching YP, Leung THY, Yau TO, Jin DY, **Ng IOL**. Rho GTPase activating protein DLC1 (deleted in liver cancer) suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 2005; 65: 8861-8868. (IF = 7.7)
209. Leung THY, Ching YP, Yam JWP, Wong CM, Yau TO, Jin DY, **Ng IOL**. Deleted in liver cancer 2, DLC2, suppresses cell transformation via inhibition of RhoA activity. Proc Natl Acad Sci USA 2005; 102:15207-15212. (IF = 10.5)
210. Lee TK, Man K, Ho JW, Wang XH, Poon RT, Xu Y, Ng KT, Chu AC, Sun CK, **Ng IO**, Sun HC, Tang ZY, Xu R, Fan ST. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 2005; 11:8458-8466. (IF = 5.62)
211. Chan DW, **Ng IOL**. Knockdown of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. J Pathol 2006; 208:372-380. (IF = 6.21)
212. Ng DCH, Chan SF, Kok KH, Yam JWY, Ching YP, **Ng IOL**, Jin DY. Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. FEBS Letters 2006; 580:191-198. (IF = 3.84)
213. Luk JM, Lam CT, **Ng IOL**, Yu MY, Che CM, Fan ST. Proteomic profiling of hepatocellular carcinoma reveals heat shock proteins (Hsp27, Hsp70, GRP78) up-regulation and associated prognostic value. Proteomics 2006; 6:1049-1057. (IF = 5.48)
214. Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CWK, **Ng IOL**, Chan GCF. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin 2006; 30:263-274. (IF = 0.516)
215. Liu CL, Fan ST, Cheung ST, Lo CM, **Ng IOL**, Wong J. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg 2006; 244: 194-203. (IF = 7.678)
216. Yam JWP, Ko FCF, Chan CY, Jin DY, **Ng IOL**. Interaction of Deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res 2006; 66: 8367-8372. (IF = 7.7)
217. Chan DW, Chan CY, Yam JWP, Ching YP, **Ng IOL**. Prickle-1 promotes degradation of Dishevelled by ubiquitination in liver cancer. Gastroenterology 2006; 131:1218-1227. (IF = 12.475)
218. Yam JWP, Ko FCF, Chan CY, Yau TO, Tung EKK, Leung THY, Jin DY, **Ng IOL**. Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology 2006; 44: 881-890. (IF = 11.446)
219. Tong ACK, **Ng IOL**, Au Yeung KM. Osteomyelitis with proliferative periostitis: an unusual case. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102:e14-19. (IF = 1.221)
220. Lee TK, Man K, Poon RTP, Lo CM, Yuen AW, **Ng IOL**, Ng KT, Leonard W, Fan ST. Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma

- aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res 2006; 66:9948-9956. (IF = 7.7)
221. Zhang P, Chan DW, Zhu YY, Li JJ, **Ng IOL\***, Wan DF\*, Gu JR Identification and characterization of a putative tumor suppressor gene, CPGL-B, in human hepatocellular carcinoma. Clin Cancer Res 2006; 12:6617-25. (\*co-corresponding authors) (IF = 6.177)
  222. Lo CM, Fan ST, Liu CL, Chan SC, **Ng IOL**, Wong J. Living donor versus deceased donor liver transplantation for early unresectable hepatocellular carcinoma. Br J Surg 2007; 94:78-86. (IF = 4.092)
  223. **Ng IOL**. The role of pathology and pathologists in the detection and management of cancer (Editorial). Hong Kong Med J 2007; 13: 5-7.
  224. Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, **Ng IOL**. Pak1 is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving JNK activation and paxillin phosphorylation. Cancer Res 2007; 67: 3601 – 3608. (IF = 7.656)
  225. Li HY, Fung KL, Jin DY, Chung SSM, Ching YP, **Ng IOL**, Sze KH, Ko BCB, Sun HZ. Solution structures, dynamics and lipid-binding of the sterile  $\alpha$ -motif (SAM) domain of the Deleted in liver cancer 2 (DLC2). Proteins-Structure Funct Bioinform 2007; 67: 1154-1166. (IF = 3.730)
  226. Wong CM, Ng YL, Lee MF, Wong CL, Cheung OF, Chan CY, Tung EK, Ching YP, **Ng IOL**. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007; 45: 1129-1138. (IF = 11.446)
  227. Chan AC, Lo CM, **Ng IOL**, Fan ST. Liver transplantation for combined hepatocellular cholangiocarcinoma. Asian J Surg 2007; 30: 143-146.
  228. Ho JC, Cheung ST, Poon AW, Lee YT, **Ng IOL**, Fan ST. Downregulation of retinol binding protein 5 (RBP5) is associated with aggressive tumor features in hepatocellular carcinoma. J Cancer Res Clin Oncol 2007; 133:929-936. (IF = 2.469)
  229. Lo CM, Liu CL, Chan SC, Lam CM, Poon RTP, **Ng IOL**, Fan ST, Wong J. A randomized controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842. (IF = 7.678)
  230. Ma S, Chan KW, Hu L, Lee TK, Wo JY, **Ng IOL**, Zheng BJ, Guan XY. Identification and characterization of tumorigenic liver cancer stem cells. Gastroenterology 2007; 132: 2542-2556. (IF = 12.475)
  231. Chen YX, Man K, Ling GS, Chen Y, Cheng Q, Sun BS, Wong OH, Lo CK, **Ng IOL**, Lau GK, Huang FP. Superior anti-tumor immunity against hepatocellular carcinoma evoked by dendritic cells devoid of interleukin-10. J Immunol 2007; 179: 6009-6015. (IF = 6.068)
  232. Sun CK, Ng KT, Sun BS, Ho JWY, Lee TK, **Ng IOL**, Poon RTP, Lo CM, Liu CL, Man K, Fan ST. The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br J Cancer 2007; 97:50-57.
  233. Leung THY, Yam JWP, **Ng IOL**. STARD13 (StAR-related lipid transfer (START) domain containing 13). Atlas Genet Cytogenet Oncol Haematol 2007; November.
  234. Wong CM, **Ng IOL**. Molecular pathogenesis of HCC. (Invited review) Liver Int 2008; 28: 160–174.
  235. Wong CCL, **Ng IOL**. Gene expression profiles of different stages of hepatocarcinogenesis. (**Invited editorial**) J Gastroenterol Hepatol 2008; 23:1-3.
  236. Cheung ST, Fan ST, Lee YT, Chow JPH, **Ng IOL**, Fong DYT, Lo CM. Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma. Transplantation 2008; 85: 81-87.
  237. Low SC, Peh WC, Muttarak M, Cheung HS, **Ng IOL**. Imaging features of hepatic angiomyolipomas. J Med Imaging Radiat Oncol 2008; 52:118-23.
  238. Chan DW, Lee JMF, Chan PCY, **Ng IOL**. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma. Int J Cancer 2008, 123:1043-1052. (IF = 4.555)

239. Man K, Lo CM, Xiao JW, Ng KT, Sun BS, **Ng IOL**, Cheng Q, Sun CK, Fan ST. The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation. Ann Surg 2008; 247: 1049-1057. (IF = 7.446)
240. Lee JMF, Wong CM, **Ng IOL**. Hepatitis B virus-associated multistep hepatocarcinogenesis - a stepwise increase in allelic alterations. Cancer Res 2008; 68: 5988-5996. (IF = 7.672)
241. Wong CCL, Wong CM, Ko FCF, Chan LK, Ching YP, Yam JWP, **Ng IOL**. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS ONE 2008; 3(July): e2779.
242. Sze KMF, Ching YP, Jin DY, **Ng IOL**. Role of a novel splice variant of MAD1, MAD1 $\beta$ , in mitotic checkpoint control in liver cancer. Cancer Res 2008; 68: 9194-9201. (IF = 7.672)
243. Tung EKK, Wong CM, Yau TO, Lee JMF, Ching YP, **Ng IOL**. HAI-2 is epigenetically down-regulated in human hepatocellular carcinoma and its Kunitz domain type 1 is critical for anti-invasive functions. Int J Cancer 2009; 124:1811-1819.
244. Yau TO, Chan CF, Lam S, Cheung OF, Ching YP, Jin DY, Sham MH, **Ng IOL**. Hepatocyte-specific activation of NF- $\kappa$ B does not aggravate chemical hepatocarcinogenesis in transgenic mice. J Pathol 2009; 217: 353-361.
245. Wong CCL, Wong CM, Tung EK, Man K, **Ng IOL**. Rho-kinase 2 (ROCK2) is frequently overexpressed in hepatocellular carcinoma and involved in tumor progression. Hepatology 2009; 49:1583-1594.
246. Hwang YY, Leung AYH, **Ng IOL**, Chan GSW, Chan KW, Tse E, Kwong YL. Protein losing enteropathy due to T-cell large granular lymphocyte leukemia. J Clin Oncol 2009;27:2097-8.
247. Chang YK, Yang W, Zhao M, Mok CC, Chan TM, Wong RW, Lee KW, Mok MY, Wong SN, **Ng IO**, Lee TL, Ho MH, Lee PP, Wong WH, Lau CS, Sham PC, Lau YL. Association of BANK1 and TNFSF4 with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun 2009; 10:414-20.
248. Yam JWP, Tse EYT, **Ng IOL**. Role and significance of focal adhesion proteins in hepatocellular carcinoma. J Gastroenterol Hepatol 2009; 24:520-530.
249. Maalouf GEL, Falissard B, Azoulay D, Callea F, Ferrell LD, Goodman ZD, Hayashi Y, Hsu HC, Hubscher SG, Kojiro M, **Ng IOL**, Paterson AC, Reynes M, Zafrani ES, Emile JF. Histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts? J Clin Pathol 2009;62:519-24.
250. Chan LK, Ko FCK, **Ng IOL\***, Yam JWP\*. Deleted in liver cancer 1 (DLC1) utilizes a previously undocumented binding site for tensin2 PTB domain interaction and required for tumor suppressive function. PLoS ONE 2009;4(5):e5572. (\*co-corresponding authors)
251. Lee TKW, Castilho A, Ma S, **Ng IOL**. Liver cancer stem cells: Implications for a new therapeutic target. Liver Int 2009; 29:955-65.
252. Xu MZ, Yao TJ, Ng IOL, Lee NPY, Chan YT, Mao M, Dai H, Burchard J, Zender L, Lowe SW, Poon RTP, Luk JM. Yes-associated protein is an independent prognostic marker associated with tumor recurrence of hepatocellular carcinoma. Cancer 2009;115:4576-85.
253. Yau TO, Leung THY, Lam S, Cheung OF, Tung EKK, Khong PL, Amy Lam Chung SK, **Ng IOL**. Deleted in Liver Cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis. PLoS ONE 2009; Aug 10;4(8):e6566.
254. Liu LX, Lee N, Chan V, Xue W, Zender L, Zhang CS, Mao M, Dai HY, Wang XL, Xu M, Lee TK, **Ng IOL**, Cheng YC, Kung HF, Lowe S, Poon RT, Wang JH, Luk JM. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 2009; 50: 1453-63.
255. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, **Ng IOL**, Fan J, Tang ZY, Sun HC, Wang XW. Gender and tumor-associated miR-26 is a predictor of hepatitis B-related hepatocellular carcinoma with poor outcome and response to interferon therapy. New Engl J Med 2009;361:1437-47.

256. Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, **Ng IOL**, Sham PC, Poon RT. Predicting prognostics in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. *BMC Cancer* 2009 Nov 3;9:389 (1-11).
257. Wong H, Yau T, Chan P, **Ng IOL**, Chan G, Hui P, Law WL, Lo CM, Hedley AJ, Epstein RJ. PPI-delayed diagnosis of gastrinoma: oncologic victim of pharmacologic success. *Pathol Oncol Res* 2010;16:87-91.
258. Hui ICF, Tung EKK, Sze KMF, Ching YP, **Ng IOL**. Rapamycin and CCI-779 inhibit mammalian target of rapamycin (mTOR) signaling in hepatocellular carcinoma. *Liver Int* 2010 ;30:65-75.
259. Ko FCF, Leung THY, Yeung YS, Wong CM, Chan LK, Poon RTP, **Ng IOL\***, Yam JWP\*. Expression and clinical relevance of deleted in liver cancer (DLC) tumor suppressors in hepatocellular carcinoma. *Liver Int* 2010; 30:139-48. (\*co-corresponding authors)
260. Yam JWP, Wong CM, **Ng IOL**. Molecular and functional genetics of hepatocellular carcinoma. *Front Biosci (Schol Ed)* 2010 Jan 1;2:117-34.
261. Sun S, Yi X, RTP Poon, Yeung C, Chan KL, **Ng IOL**, Day PJR, Luk JM. Proteomics of hepatocellular carcinoma: serum vimentin as a surrogate marker for small tumors ( $\leq 2$ cm). *J Proteome Res* 2010; 9:1923-30. (IF = 5.69)
262. Yang W, Shen N, Ye DQ, Liu Q, Zhang Y, Qian XX, Hirankarn N, Ying D, Pan HF, Mok CC, Chan TM, Wong RW, Lee KW, Mok MY, Wong SN, Leung AM, Li XP, Avihingsanon Y, Wong CM, Lee TL, Ho MH, Lee PP, Chang YK, Li PH, Li RJ, Zhang L, Wong WH, **Ng IOL**, Lau CS, Sham PC, Lau YL; Asian Lupus Genetics Consortium (ALGC). Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. *PLoS Genet* 2010 Feb 12;6(2):e1000841.
263. Chan CP, Mak TY, Chin KT, **Ng IOL**, Jin DY. N-Linked glycosylation is required for optimal proteolytic activation of liver-enriched transcription factor CREB-H. *J Cell Sci* 2010; 123:1438-48. (IF = 6.25)
264. Wong CC, Wong CM, Au SLK, **Ng IOL**. RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N' Rho move it. *Liver Int* 2010; 30:642-656.
265. Ko FCK, Chan LK, Tung EKK, Lowe SW, **Ng IOL\***, Yam JWP\*. Akt phosphorylation of Deleted in Liver Cancer 1 abrogates its suppression in liver cancer tumorigenesis and metastasis. *Gastroenterology* 2010; 139:1397-1407. (\*co-corresponding authors)
266. Lee NP, Poon RT, Shek FH, **Ng IOL**, Luk J. Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. *Biochem Biophys Acta* 2010; 1806:138-45.
267. Leung THY, Yam JWP, Chan LK, Ching YP, **Ng IOL**. DLC2 (Deleted in liver cancer 2) suppresses cell growth via regulation of Raf-1-ERK1/2-p70S6K signaling pathway. *Liver Int* 2010; 30:1315-23.
268. Ko FCF, **Ng IOL**, Yam JWP. DLC1 (deleted in liver cancer 1). *Atlas Genet Cytogenet Oncol Haematol* 2010 May. URL: <http://AtlasGeneticsOncology.org/Genes/DLC1ID40328ch8p22.html>
269. Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J, Yao J, Yan M, Li J, Yao M, **Ng IOL**, He X. MicroRNA-125b suppressed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. *Hepatology* 2010; 52:1731-40.
270. Wong CCL, Wong CM, Tung EKK, Au SLK, Lee JMF, Poon RTP, Man K, **Ng IOL**. MiR-139 suppresses metastasis and progression of hepatocellular carcinoma through regulation of Rho-kinase 2 (ROCK2). *Gastroenterology* 2011;140:322-31. (**Top 2% of published articles in biology and medicine, Faculty of 1000 [F1000]**).
271. Lee TKW, Castilho A, Cheung VCH, Tang KH, Ma S, **Ng IOL**. Lupeol targets liver tumor initiating cells through PTEN modulation. *Hepatology* 2011;53:160-70.
272. Yang J, Yang W, Hirankarn N, Ye DQ, Zhang Y, Pan HF, Mok CC, Chan TM, Wong RW, Mok MY, Lee KW, Wong SN, Leung AM, Li XP, Avihingsanon Y, Rianthavorn P, Deekajorndej T, Suphapeetiporn K, Shotlersuk V, Baum L, Kwan P, Lee TL, Ho MH, Lee PP, Wong WH, Zeng S, Zhang J, Wong CM, **Ng IO**, Garcia-Barceló MM, Cherny SS, Tam PK, Sham PC, Lau CS, Lau

- YL. ELF1 is associated with systemic lupus erythematosus in Asian populations. Hum Mol Genet 2010, Nov 2. [Epub ahead of print]
273. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, **Ng IOL**, Man K, Wong N, To KF, Zheng BJ, Lai PB, Chan KW, Guan XY. miR-130b promotes CD133+ liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010;7: 694-707.
274. Lee TK, Murthy SR, Cawley NX, Dhanvantari S, Hewitt SM, Lou H, Lau T, Ma S, Huynh T, Wesley RA, **Ng IOL**, Pacak K, Poon RT, Loh YP. Carboxypeptidase E splice isoform: a novel tumor inducer and biomarker for predicting metastasis and recurrence in different cancers. J Clin Invest 2011;121:880-92. (Recommended by F1000Prime)
275. Chan SC, Lo CM, Ng KK, **Ng IOL**, Yong BH, Fan ST. Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein. Liver Transpl 2011; 17:115-21.
276. Wong CM, Wong CCL, Ng YL, Ko FCF, **Ng IOL**. Transcriptional repressive H3K9 and H3K27 methylations are essential for DNMT1-mediated DNA methylation recovery. PLoS ONE 2011;6(2): e16702.
277. Zhang Y, Yang W, Mok CC, Chan TM, Wong RW, Mok MY, Lee KW, Wong SN, Leung AM, Lee TL, Ho MH, Lee PP, Wong WH, Yang J, Zhang J, Wong CM, **Ng IOL**, Garcia-Barceló MM, Cherny SS, Tam PK, Sham PC, Lau CS, Lau YL. Two missense variants in UHRF1BP1 are independently associated with systemic lupus erythematosus in Hong Kong Chinese. Genes Immun. 2011 Feb 17. [Epub ahead of print]
278. Chan J, Ko FC, Yeung YS, **Ng IOL**, Yam JW. Integrin-linked Kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS ONE 2011, 2011 Feb 9;6(2):e16984.
279. Mak GW, Chan MM, Leong VY, Lee JM, Yau TO, **Ng IOL**, Ching YP. Overexpression of a novel activator of PAK4, CDK5RAP3, promotes hepatocellular carcinoma metastasis. Cancer Res 2011 Mar 8. [Epub ahead of print]
280. Arzumanyan A, Friedman T, **Ng IOL**, Clayton MM, Lian Z, Feitelson MA. Does hepatitis B x antigen (HBx) promote the appearance of liver cancer stem cells? Cancer Res 2011; 71:3701-8. [Epub ahead of print]
281. Seto WK, Ng M, Chan P, **Ng IO**, Cheung SC, Hung IF, Yuen MF, Lai CL. Ketamine-induced cholangiopathy: a case report. Am J Gastroenterol 2011;106:1004-5.
282. Sze KM, Wong KL, Chu GK, Yau TO, **Ng IOL**. Loss of PTEN enhances cell invasion and migration through AKT/Sp-1 transcription factor/MMP2 activation and has clinicopathologic significance in hepatocellular carcinoma. Hepatology 2011;53:1558-69.
283. Gao P, Wong CCL, Tung EKK, Lee JMF, Wong CM, **Ng IOL**. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 2011; 54:1177-84. [Epub ahead of print]
284. Luk SU, Lee TK, Liu J, Lee DT, Chiu YT, Ma S, **Ng IO**, Wong YC, Chan FL, Ling MT. Hemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One 2011;6(5):e19804. Epub 2011 May 16.
285. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, **Ng IO**. CD24<sup>+</sup> liver tumor-initiating cells drive self-renewal and tumor initiation through Stat3-mediated nanog regulation. Cell Stem Cell 2011; 9:50-63 (IF 25.9; Rank 4 of 162 in Cell Biology Category; a '**Featured Research' paper in Cell Stem Cell in 2012 September**).
286. Arzumanyan A, Friedman T, Kotei E, **Ng IO**, Lian Z, Feitelson MA. Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer. Oncogene 2012;31: 563-72. [Epub ahead of print]
287. Chew V, Chen JM, Lee DM, Loh E, JMF Lee, Lim KH, Weber A, Slankamenac K, Poon RTP, Yang H, Toh HC, Lucien L, Ooi PJ, Heikenwälder M, **Ng IOL**, Nardin A, Abastado JP. An

- immune gene signature predictive for survival in early hepatocellular carcinoma: role of chemokine-driven lymphocyte infiltration. Gut 2012;61:427-38. [Epub ahead of print] (IF = 10.614)
288. Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, Fraley SI, Wong CM, Khoo US, **Ng IO**, Wirtz D, Semenza GL. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A 2011 Sep 27;108:16369-74.
  289. Tung EKK, Mak CKM, Fatima S, Zhao H, Lee JMF, Lo RCL, Zhang CS, Mao M, Dai H, Carolyn, Poon RTP, Yuen MF, Lai CL, Li JJ, Luk JMC, **Ng IOL**. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liv Int 2011; 31:1494-1504.
  290. Chan LK, Ko FCF, Sze KM, **Ng IOL\***, Yam JW\*. Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo. PLoS ONE 2011;6:e25547. (Co-corresponding authors)
  291. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, **Ng IO**, Man K, To KF, Lai PB, Lo CM, Guan XY, Chan KW. CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth and self-renewal through neurotensin/IL-8/CXCL1 signaling. Hepatology 2012; 55:807-20. [Epub ahead of print]
  292. Li R, Yang WL, Zhang J, Hirankarn N, Pan HF, Mok CC, Chan TM, Wong RWS, Mok MY, Lee KW, Wong SN, Leung AMH, Li XP, Avihingsanon Y, Lee TL, Ho MHK, Lee PPW, Sang WH Wong, Wong CM, **Ng IOL**, Yang J, Li PH, Zhang Y, Zhang L, Li WX, Baum L, Kwan P, Rianthavorn P, Deekajorndej T, Suphapeetiporn K, Shotlersuk V, Garcia-Barceló M, Cherny SS, Tam PKH, Sham PC, Lau CS, Shen N, Lau YL, Ye DQ. Association of CD247 with systemic lupus erythematosus in Asian Populations: A genome wide association study. Lupus 2011; Oct 17. [Epub ahead of print]
  293. Tse EYT, Ko FCK, Tung EKK, Chan LK, Lee TKW, Hui LJ, Ngan ESW, Wong AST, **Ng IOL**, Yam JWP. Caveolin-1 promotes hepatocellular carcinoma tumorigenesis, migration and invasion via Met-ERK1/2 pathway. J Pathol 2012; 226:645-53. [Epub ahead of print].
  294. Hao K, Lamb J, Zhang C, Xie T, Wang K, Zhang B, Chudin E, Lee NP, Mao M, Zhong H, Greenawalt D, Ferguson MD, **Ng IO**, Sham PC, Poon RT, Molony C, Schadt EE, Dai H, Luk JM. Clinicopathologic and gene expression parameters predicts liver cancer prognosis. BMC Cancer 2011;11:481.
  295. Lo RCL, **Ng IOL**. Hepatocellular tumors – Immunohistochemical analyses for classification and prognostication. Chin J Cancer Res 2011; 43:245-253.
  296. Wong CM, Wong CCL, Lee JMF, Fan DNY, Au SLK, **Ng IOL**. Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 2012; 55:1453-61. [Epub ahead of print] (**Featured on cover**) (**Faculty of 1000 (F1000) - the top 2% of published articles in biology and medicine**).
  297. Chan KY, Wong CM, Kwan JS, Lee KM, Cheung KW, Yuen MF, Lai CL, Poon RT, Sham PC, **Ng IOL**. GWAS identified 8p12 locus that is associated with susceptibility to hepatocellular carcinoma in Southern Chinese patients with chronic HBV infection. PLoS One 2011;6(12):e28798. Epub 2011 Dec 8.
  298. Chan FK, Chung SS, **Ng IO**, Chung SK. The RhoA GTPase-activating protein DLC2 modulates RhoA activity and hyperalgesia to noxious thermal and inflammatory stimuli. Neurosignals 2012;20(2):112-26. [Epub ahead of print]
  299. Wong CM, **Ng IOL**. Reply to: "Deregulation of microRNAs expression occurs in stages of multiple hepatocarcinogenesis: why it is different?". J Hepatol 2012; doi: 10.1016/j.jhep.2011.12.005.
  300. Fatima S, Lee NP, Tsang FH, Kolligs FT, **Ng IO**, Poon RT, Fan ST, Luk JM. Dickkopf 4 (DKK4) acts on Wnt/ $\beta$ -catenin pathway by influencing  $\beta$ -catenin in hepatocellular carcinoma. Oncogene 2012; 31:4233-44 [Epub ahead of print]

301. Yuan K, Lian Z, Sun B, Clayton MM, **Ng IO**, Feitelson MA. Role of miR-148a in hepatitis B associated hepatocellular carcinoma. *PLoS One*. 2012;7(4):e35331. [Epub 2012 Apr 9].
302. Tung EKK, Wong BYC, Yau TO, **Ng IOL**. Upregulation of the Wnt co-receptor LRP6 promotes hepatocarcinogenesis and enhances cell invasion. *PLoS ONE* 2012; 7(5):e36565. [Epub 2012 May 3].
303. Au SLK, Wong CCL, Lee JMF, Fan DNY, **Ng IO\***, Wong CM\*. Enhancer of zeste homolog 2 (EZH2) epigenetically silences multiple tumor suppressor miRNAs to promote liver cancer metastasis. *Hepatology* 2012; 55:1453-61. (\* co-corresponding authors)
304. Lai WL, Hung WY, Wong LL, Zhou Y, Leong VY, Lee JM, **Ng IO**, Jin DY, Ching YP. The centrosomal protein Tax1 binding protein 2 is a novel tumour suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2. *Hepatology* 2012; 56:1770-81. [Epub ahead of print]
305. Lee TK, Cheung VC, **Ng IO**. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. *Cancer Lett* 2012; May 8. [Epub ahead of print]
306. Chen L, Liu C, Ko FC, Xu N, **Ng IO**, Yam JW, Zhu G. Solution structure of the PTB domain of human Tensin2 in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode. *J Biol Chem* 2012; 287:26104-14. [Epub ahead of print]
307. Lee CW, Wong LL, Tse EY, Liu HF, Leong VY, Lee JM, Hardie DG, **Ng IO**, Ching YP. AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. *Cancer Res* 2012;72:4394-404. [Epub ahead of print]
308. Lam CY, Yip CW, Poon TC, Cheng CK, Ng EW, Wong NC, Cheung PF, Lai PB, **Ng IO**, Fan ST, Cheung ST. Identification and characterization of tropomyosin 3 associated with granulin-epithelin precursor in human hepatocellular carcinoma. *PLoS One* 2012;7:e40324.
309. Sze KMF, Chu GKY, **Ng IOL**. C-terminal truncated HBx is associated with metastasis and enhances invasiveness via C-Jun/MMP10 activation in hepatocellular carcinoma. *Hepatology* 2013;57:131-139. [Epub ahead of print].
310. Ma W, Wong CCL, Tung EKK, Wong CM, **Ng IOL**. RhoE is frequently downregulated in HCC and suppresses HCC invasion through antagonizing the Rho/ROCK/MYPT pathway. *Hepatology* 2013;57:152-161. [Epub ahead of print].
311. Tung EK, **Ng IOL**. Reply to “Considerations in the significance of Dickkopf-1 levels in human hepatocellular carcinoma”. *Liver Int* 2012; Aug 16. [Epub ahead of print].
312. Mak GW, Lai WL, Zhou Y, Li M, **Ng IO**, Ching YP. CDK5RAP3 is a Novel Repressor of p14ARF in hepatocellular carcinoma cells. *PLoS One* 2012;7(7):e42210. Epub 2012 Jul 31.
313. Fan DNY, Tsang FH, Tam AH, Au SL, Wong CC, Wei L, Lee JM, He X, **Ng IO**, Wong CM. Histone lysine methyltransferase, SUV39H1, promotes HCC progression and is negatively regulated by microRNA-125b. *Hepatology* 2013;57:637-47. [Epub ahead of print].
314. Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, **Ng IO**, Nardin A, Abastado JP. TLR3-expressing tumor parenchyma and infiltrating NK cells promote tumor control in hepatocellular carcinoma patients. *J Natl Cancer Inst* 2012;104:1796-807. [Epub ahead of print].
315. Tung EK, **Ng IO**. Significance of serum DKK1 as a diagnostic biomarker in hepatocellular carcinoma. *Future Oncol* 2012;8:1525-8.
316. Wong CM, Kai AK, Tsang FH, **Ng IO**. Regulation of hepatocarcinogenesis by microRNAs. *Front Biosci (Elite Ed)* 2013;5:49-60.
317. Yang W, Tang H, Zhang Y, Tang X, Zhang J, Sun L, Yang J, Cui Y, Zhang L, Hirankarn N, Cheng H, Pan HF, Gao J, Lee TL, Sheng Y, Lau CS, Li Y, Chan TM, Yin X, Ying D, Lu Q, Leung AM, Zuo X, Chen X, Tong KL, Zhou F, Diao Q, Tse NK, Xie H, Mok CC, Hao F, Wong SN, Shi B, Lee KW, Hui Y, Ho MH, Liang B, Lee PP, Cui H, Guo Q, Chung BH, Pu X, Liu Q, Zhang X, Zhang C, Chong CY, Fang H, Wong RW, Sun Y, Mok MY, Li XP, Avihingsanon Y, Zhai Z, Rianthavorn P, Deekajorndej T, Suphapeetiporn K, Gao F, Shotelersuk V, Kang X, Ying

- SK, Zhang L, Wong WH, Zhu D, Fung SK, Zeng F, Lai WM, Wong CM, **Ng IO**, Garcia-Barceló MM, Cherny SS, Shen N, Tam PK, Sham PC, Ye DQ, Yang S, Zhang X, Lau YL. Meta-Analysis Followed by Replication Identifies Loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as Associated with Systemic Lupus Erythematosus in Asians. Am J Hum Genet 2013; 92:41-51.
318. Lo RCL, Chan SC, Chan KL, Chiang AK, Lo CM, **Ng IOL**. Post-transplant lymphoproliferative disorders in liver transplant recipients - A clinicopathologic study. J Clin Pathol 2013; 66:392-8.
319. Ko FC, Chan LK, Man-Fong Sze K, Yeung YS, Yuk-Ting Tse E, Lu P, Yu MH, **Ng IOL**, Yam JW. PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. Nat Commun 2013;4:1618.
320. Au SL, **Ng IO**, Wong CM. Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins. Front Med 2013;7:231-41.
321. Au SL, Wong CCL, Lee JM, Wong CM, **Ng IO**. EZH2-mediated H3K27me3 is involved in epigenetic repression of Deleted in Liver Cancer 1 in human cancers. PLoS One 2013 Jun 27;8(6):e68226.
322. Lo RC, **Ng IO**. Hepatic progenitor cells: Their role and functional significance in the new classification of primary liver cancers. Liver Cancer 2013;2:84-92.
323. Wong CC, Kai AK, **Ng IO**. The impact of hypoxia in hepatocellular carcinoma metastasis. Front Med 2013 Nov 14. [Epub ahead of print]
324. Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, **Ng IO**, Sun H, Qin L, Qiu S, Lee JM, Lo CM, Man K, Yang Y, Yang Y, Yang Y, Zhang Q, Zhu X, Li N, Wang Z, Ding G, Zhuang SM, Zheng L, Luo X, Xie Y, Liang A, Wang Z, Zhang M, Xia Q, Liang T, Yu Y, Cao X. Hepatic RIG-I predicts survival and interferon- $\alpha$  therapeutic response in hepatocellular carcinoma. Cancer Cell 2013 Dec 18. [Epub ahead of print].
325. Sze KM, Chu GK, Mak QH, Lee JM, **Ng IO**. Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has suppressive role in mitotic checkpoint signaling in HCC. J Pathol 2013 Dec 26. [Epub ahead of print]

#### Manuscripts in press:

1. Lau EY, **Ng IO**, Lee TK. Cancer associated fibroblasts and hepatocellular carcinoma. J Liver: Dis & Transplantation 2013; Editorial.
2. Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, Tong C, **Ng IOL**. Blockade of CD47 mediated CTSS-PAR2 signaling provides a therapeutic target for hepatocellular carcinoma. Manuscript under review, Hepatology.

<b>2. EDITORSHIP OF SCHOLARLY JOURNALS AND BOOKS</b>
--

**Journal Editorial Boards**

2013 -	Journal of Hepatocellular Carcinoma (Honorary Editorial Board)
2009 - 2011	Hepatology
2009 -	Genes and Cancer
2008 - 2011	<b>Academic Editor</b> , PLoS ONE
2007 - 2012	<b>Associate Editor</b> , Liver International (Official journal of International Association for the Study of the Liver)
2000 -	Journal of Gastroenterology and Hepatology
2000 -	Asian Journal of Surgery
2002 - 2009	Asian Journal of Oral and Maxillofacial Surgery
1999 - 2005	Journal of Clinical Oncology (Chinese version)
2009 Dec	Proceedings of the National Academy of Science, USA - Direct Submission Editor

**Ad Hoc Reviewer for International Journals (in alphabetical order)**

American Journal of Transplantation, Cancer, Cancer Cell, Cell Report, Cancer Journal, Cancer Letters, Cancer Research, Clinical Cancer Research, Differentiation, The European Journal of Cancer, Expert Reviews in Molecular Medicine, Gastroenterology, Gene, Hepatology, Histology and Histopathology, Human Pathology, International Journal of Cancer, JAMA, Journal of Biomedical Science, Journal of Cancer Research and Clinical Oncology, Journal of Cellular and Molecular Medicine, Journal of Experimental & Clinical Cancer Research, Journal of Hepatology, Life Sciences, Liver, Nature Medicine, Nature Signaling, Neoplasia, Oncogene, and World Journal of Surgery.

**International Advisor to Books**

General and Systematic Pathology by Underwood JCE and Cross SS, 5<sup>th</sup> edition, Elsevier 2009.

<b>3. INVITED LECTURES AND PRESENTATION IN INTERNATIONAL/REGIONAL CONFERENCES/INSTITUTIONS</b>
--

- 'Pathology of hepatocellular carcinoma'**, University of Calgary, Canada, 1990
- 'Liver tumours'**, Day Course on Liver Pathology, the International Academy of Pathology, 1992
- 'Pathobiological prognostic factors in hepatocellular carcinoma'**, 4th Congress of the Asia Pacific Association of Societies of Pathologists, Beijing, 1994
- 'Prognostic pathobiological factors in hepatocellular carcinoma'**, International Symposium on Hepatology, Hong Kong, 1994
- 'p53 gene mutation in hepatocellular carcinoma in Hong Kong'**, Third Joint Meeting of International Academy of Pathology Chinese Division and Chinese Society of Pathology, Beijing, China, 1994
- 'Pathology and pathological prognostic factors of hepatocellular carcinoma'**, First Hong Kong International Cancer Congress, Hong Kong, 1994
- 'p53 gene mutation in hepatocellular carcinoma in Hong Kong'**, XX International Congress of International Academy of Pathology, 1994
- 'Possible causes for the better survival in female patients with hepatocellular carcinoma'**, International Symposium of Hepatology 1995, Hong Kong, 1995
- 'Epidemiologic aspects in hepatocellular carcinoma'**, Second Hong Kong International Cancer Congress, Hong Kong, 1995
- 'Molecular aspects of hepatocellular carcinoma'**, 3rd International Conference of Gastroenterology, Hong Kong & Shanghai, November, jointly organized by Gastroenterology Societies of America, Australia, Hong Kong, Japan and China, 1995
- 'Role of insulin-like growth factor II in hepatocellular carcinoma'**, International Symposium on Hepatology, November, Hong Kong, 1996
- 'Contribution of a histopathology laboratory in patient care'**, Scientific Meeting, the Institute of Biomedical Science, Hong Kong 1996
- 'Expression of multidrug resistance gene in cancers - a perspective in oral and liver cancers'**, School of Basic Medical Sciences, Beijing Medical University, China, August 1997
- 'Determinants of long term survival in hepatocellular carcinoma'**, International Symposium in Hepatology, Beijing, China, August 1997
- 'Molecular and cellular pathology of hepatocellular carcinoma'**, Beijing Medical University, Beijing, China, August 1997
- 'Expression of multidrug resistance gene in oral cancers'**, University of California, San Francisco, U.S.A., April 1997
- 'Hepatocellular carcinoma - determinants of long term survival'**, 11th Biennial Congress, Asian Surgical Association, March, Hong Kong, 1997
- 'Molecular pathology of hepatocellular carcinoma'**, Shanghai Cancer Institute, Shanghai, China, December 1997
- 'Molecular and cellular pathology of hepatocellular carcinoma'**, Alimentary Disease Week Hong Kong (jointly organized by American Gastroenterological Association, Gastroenterological Society of Australia, Hong Kong Society of Gastroenterology, the Japanese Society of Gastroenterology, Hong Kong Association for the Study of Liver Diseases and International Conference on Ulcer Research), Hong Kong, December 1997
- 'Molecular events in hepatocellular carcinoma - p53 and p21'**, 5<sup>th</sup> Hong Kong International Cancer Congress, Hong Kong, November 1998

- ‘Differential higher expression of VEGF-receptor Flt-1 but not VEGF is present in hepatocellular carcinoma’**, Plenary presentation, Annual meeting, International Association for the Study of Liver Diseases, Chicago, November 1998
- ‘Molecular aspects of hepatocellular carcinoma’**, Cancer Institute, West China University of Medical Sciences, Chengdu, July 1999
- ‘Angiogenesis and hepatocellular carcinoma’**, Henan Medical School, China, February 2000
- ‘Gene transfer targeted to hepatocellular carcinoma’**, Henan Medical School, China, February 2000
- ‘Microsatellite alterations and expression of cell cycle regulators in oral cancer’**, University of California, San Francisco, U.S.A., March 2000
- ‘The prognostic pathobiological features and angiogenesis in hepatocellular carcinoma’**, Fourth Military Medical University, Xian, China, April 2000
- ‘Targeted gene therapy and molecular aspects in hepatocellular carcinoma’**, Fourth Military Medical University, Xian, China, April 2000
- ‘Molecular events in the pathogenesis of hepatocellular carcinoma’**, Liver Diseases in the New Millennium (Fourth Shanghai International Symposium on Liver Cancer and Hepatitis), Shanghai, China, September 2000
- ‘Histological activity of noncancerous livers in hepatocellular carcinoma’**, Shanghai Second Medical University, Shanghai, China, December 2000
- ‘High-density allelotyping of chromosome 8p in hepatocellular carcinoma’**, Liver Cancer Institute, Fudan University, Shanghai, China, December 2000
- ‘Molecular pathology of hepatocellular carcinoma in Hong Kong’**, Molecular Genetic Basis of Cancer, Advanced Study Institute, Hong Kong, January 2001
- ‘Molecular genetic study of hepatocellular carcinoma’**, 2nd Scientific Meeting, Centre for the Study of Liver Disease, HKU, Hong Kong, February 2001
- ‘Molecular genetic studies of hepatocellular carcinoma’ (PLENARY SESSION)**, Asian-Pacific Conference of Tumor Biology 2001, Beijing, China, September 2001
- ‘Significance of histological activity in HBV-associated hepatocellular carcinoma’**, 3rd Scientific Meeting, HKU Centre for the Study of Liver Disease, Hong Kong, February 2002
- ‘Cirrhosis and hepatocellular carcinoma’**, Shanghai International Symposium of Cirrhosis and Its Complications, Shanghai, China, March 2002
- ‘Molecular advances in hepatocellular carcinoma’**, Nanjing University, Nanjing, China, October 2002
- ‘Hepatocellular carcinoma - Molecular oncology’**, 9<sup>th</sup> Hong Kong International Cancer Congress and 18<sup>th</sup> World Congress of the International Society for Digestive Surgery, Hong Kong, December 2002
- ‘Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma’**, 4th Scientific Meeting, HKU Centre for the Study of Liver Disease, Hong Kong, February 2003
- ‘Genetic alterations in hepatocellular carcinoma’**, Institute of Liver Studies, King's College Hospital, London, U.K., March 2003
- ‘Characterization of candidate tumour suppressor genes in hepatocellular carcinoma’**, Pasteur Institute, Paris, France, March 2003
- ‘Novel tumour suppressor genes in hepatocellular carcinoma’**, Inserm U434, Institut de génétique moléculaire, Paris, France, March 2003
- ‘Novel molecular approaches to diagnosis and management of liver cancer’**, American Society for Investigative Pathology - Experimental Biology 2003, at Workshop on ‘Liver Pathobiology: Molecular and Cellular Basis of Liver Cancer’, San Diego, USA, April 2003

- ‘Role of the pathologist in hepatocellular carcinoma’**, Hong Kong Surgical Forum, University of Hong Kong, Hong Kong, July 2003
- ‘Frequent chimerism in transplanted livers’**, 5th Scientific Meeting, HKU Centre for the Study of Liver Disease, Hong Kong, February 2004
- ‘Molecular studies in hepatocellular carcinoma’**, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, USA, March 2004
- ‘Genetic instability and novel genes in hepatocellular carcinoma’**, Genomics, Proteomics and Therapeutics in Cancer Research Conference, Cancer Research Centre, Faculty of Medicine, The University of Hong Kong, October 2004
- ‘RNA interference’**, Hong Kong International Cancer Congress, Hong Kong, November 2004
- ‘Molecular and genetic studies of hepatocellular carcinoma’**, Frontiers in Biomedical Research, Faculty of Medicine, The University of Hong Kong, December 2004
- ‘Chimerism in transplanted livers’**, Asian Pacific Association for the Study of Liver Disease, New Delhi, India, December 2004
- ‘Pathology of hepatocellular carcinoma’**, Surgical Workshop in HCC, 4<sup>th</sup> International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences, Hong Kong, December 2004
- ‘Molecular studies of HCC’**, 4<sup>th</sup> International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences, Hong Kong, December 2004
- ‘Chromosomal instability and novel genes in HCC’ (State-of-the-Art Lecture)**, 5th Scientific Meeting, HKU Centre for the Study of Liver Disease, Hong Kong, January 2005
- ‘RNA interference in hepatocellular carcinoma’**, Fourth Asia-Pacific International Academy of Pathology Congress (IAP2005), Beijing, August 2005
- ‘Pathology and molecular genetics of liver cancer’**, Symposium on liver cancer: Hope for our future generations, The Hong Kong Anti-Cancer Society, Hong Kong, August 2005
- ‘Virus to cancer - how?’**, World Congress of Gastroenterology 2005 Meeting ‘Global Goals in Gastroenterology: Expanding Horizons for the 21st Century’, Montréal, Canada, September 2005
- ‘Molecular and genetic alterations in hepatocellular carcinoma’**, Symposium on Advances in Cancer Biology, 18<sup>th</sup> Asia Pacific Cancer Conference, Seoul, Sept 2005
- ‘Multistep process of hepatocarcinogenesis’**, Frontiers in Biomedical Research, Faculty of Medicine, The University of Hong Kong, December 2005
- ‘Pathological diagnosis of HCC and beyond’**, Shanghai - Hong Kong International Liver Congress 2006, Shanghai, March 2006
- ‘HBV and genetic alterations in hepatocellular carcinoma’**, Princess Margaret Hospital, University of Toronto, March 2006
- ‘Molecular pathology and genetic alterations in hepatocellular carcinoma’**, Laboratory of Experimental Carcinogenesis, National Institute of Health, Bethesda, USA, April 2007
- ‘Epigenetic gene expression profiling to identify frequently silenced candidate tumor suppressor genes in cancers’**, 5<sup>th</sup> Asia Pacific International Academy of Pathology Congress, Singapore, May 2007
- ‘Molecular characterization of human hepatocellular carcinoma – Tumor suppressor genes’**, American Association for Cancer Research 2008 Annual Meeting, San Diego, USA, April, 2008
- ‘Molecular pathology and genetic alterations of liver cancer’**, International Liver Congress 2008, Hong Kong, June 2008
- ‘HBV-associated hepatocarcinogenesis and ROCK2 in HCC’**, Laennac Society meeting 2008, Padua, Italy, July 2008

- ‘Carcinogenesis of hepatocellular carcinoma’**, 2008 International Liver Cancer Symposium, Seoul, Korea, September 2008
- ‘Molecular basis of cancer – tumor suppressor genes’**, Yongsei University, Seoul, Korea, September 2008
- ‘Liver cancer as a curable/deadly disease from the perspective of histopathology and research in tumour characteristics’**, Consultants’ Meeting on development of guidelines for the palliative management of common cancers using radiotherapy in limited resource settings: liver cancer, IAEA Headquarters, The United Nations, Vienna, Austria, October 2008
- ‘Molecular pathology and genetic alterations in liver cancer’**, Singapore Cancer Symposium, Institute of Molecular and Cell Biology, Singapore, October 2008
- ‘Molecular pathology and genetic alterations in liver cancer’**, Mini-symposium, Institute of Biochemistry and Cell Biology, SIBS, Shanghai, October 2008
- ‘HBx and HCC’**, 19<sup>th</sup> Conference, Asian Pacific Association for the Study of Liver, Hong Kong, February 2009
- ‘Molecular pathogenesis of hepatocellular carcinoma’**, Frontier in Medical Sciences 2009 – Symposium on New Concepts and Approaches in Primary Liver Cancer Research, Shanghai, October 2009
- ‘Molecular pathology of liver cancer’**, Department of Oncology, Hammersmith Hospital, Imperial College, London, UK, November 2009
- ‘Cancer stem cell and carcinogenesis’**, Avison Biomedical Symposium 2010, Yonsei University College of Medicine, Seoul, February 2010
- ‘Molecular pathogenesis of hepatocellular carcinoma’**, 20<sup>th</sup> Conference, Asian Pacific Association of the Study of the Liver, Beijing, March 2010
- ‘MicroRNA in liver cancer’**, Laennec Liver Pathology Society Meeting, Seoul, Korea, May 2010
- ‘Wnt/ $\beta$ -catenin cell signaling in HCC’**, Laennec Liver Pathology Society Meeting, Seoul, Korea, May 2010
- ‘MicroRNA in liver cancer’**, Shangdong University, September 2010
- ‘Liver nodules – a diagnostic approach’**, Shangdong University, September 2010
- ‘Molecular & genetic advances in hepatocellular carcinoma - Molecular and genetic diagnostic and prognostic markers in HCC’**, International Liver Symposium 2011, Gurgaon, India, August 2011.
- ‘HCC: Biomarkers & Stratification’**, Fifth Annual Conference, International Liver Cancer Association, Hong Kong, September 2011
- ‘Molecular genetic study in HCC: MicroRNA deregulation in multistep hepatocarcinogenesis’** Eastern Hepatobiliary Surgery Hospital, Shanghai, October, 2011
- ‘Do primary HCCs already harbor specific genetic alterations that confer a metastatic capacity to the tumors?’** Laennec Liver Pathology Society Meeting, Heidelberg, Germany, May 2012
- ‘Liver cancer stem cells in hepatocellular carcinoma’**, 2012 Cold Spring Harbor Asia Conference on Liver Metabolism, Disorders and Cancer, Suzhou, China, May 2012
- ‘MicroRNA deregulation in multistep hepatocarcinogenesis’**, Symposium on Translational Medicine for Cancer of Digestive Systems, 2012 Forum of Sino-American Translational Medicine, Shanghai, June 2012
- ‘Pathology and pathogenesis of HCC’**, The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting - A Bridge to a Consensus on HCC Management, Shanghai, China, July 2012
- ‘Liver cancer stem cells in hepatocellular carcinoma’**, The 7th Princess Chulabhorn International Science Congress -Cancer: from Basic Research to Cure, Bangkok, Thailand, November 2012
- ‘C-terminal truncated HBx is associated with cell invasiveness via c-Jun/MMP10 activation in HCC’**, Annual Meeting, the Laennec Liver Pathology Society Annual Meeting, Singapore, May14-17, 2013.

**‘HCC research: Molecular drivers and signalling pathway’**, 23rd Conference of the Asian Pacific Association for the Study of the Liver (APASL), Singapore, June 6-10, 2013

**‘Molecular pathogenesis of hepatocellular carcinoma’**, 19th Annual Meeting, Korean Association for the Study of the Liver, Seoul, Korea, June 13-15, 2013

**‘Recent updates in liver cancer stem cells’**, the 8th IAP Asia Pacific Congress, Busan, South Korea, September 6, 2013

**‘HCC classification based on pathological markers’**, International Liver Cancer Association 7<sup>th</sup> Annual Conference - ILCA-EASL-NCI-AASLD Workshop on Molecular Classification and Biomarkers in HCC, Washington, DC, USA, September 12, 2013

**‘Liver Cancer Stem Cells’**, 2013 Shanghai International Symposium on Cancer Stem Cells, Shanghai, China, October 17-19, 2013.

<b>4. INTERNATIONAL STANDING AND CONTRIBUTIONS TO KNOWLEDGE IN THE FIELD</b>
--

**A. Visiting/Honorary Professorship**

1997 - 1998 Visiting Professor, Shanghai Cancer Institute, Shanghai  
 1998 - 1999 Mrs. Gordon Wu Exchange Professorship, University of Hong Kong  
 & 2008 - 2009

**B. International Study Group**

2000 - International Liver Cancer Study Group with researchers from France, Germany, Italy, UK, USA, Japan, Taiwan, Hong Kong and South Africa.  
 (On classification of hepatocellular carcinoma)  
 2002 - International Cooperative Study Group on Hepatocellular Carcinoma (The University of Texas M.D. Anderson Medical Center, Mayo Clinic, Hôpital Beaujon, Paris, and University of Hong Kong Medical Center)  
 2007 - Laennec Society on Liver Pathology (an International liver pathology group with members from >10 countries)

**C. Grant review**

2002 Reviewer for grant proposals of the Italian Association for Cancer Research  
 2004 - Hong Kong Research Grants Council (HKRGC)  
 2004 Hong Kong Baptist University  
 2005 Biomedical Research Council (BMRC), A\*STAR, the Agency for Science, Technology and Research, Singapore  
 2006 - 2012 Member, Hong Kong Research Grants Council (Biology and Medicine Panel)  
 2007 - 2009 Member, Research Grants Council Selection Committee (National Natural Science Foundation of China NSFC/RGC Joint Research Scheme)  
 2007 - present Member, Grant Review Board, Research Office, Food and Health Bureau, The Government of Hong Kong SAR  
 2008 - Ad Hoc reviewer, Association for International Cancer Research, UK.

**D. Organizing Committees of Scientific Meetings**

1996 - 1997 Member, Organizing Committee, 110th Anniversary Scientific Congress, University of Hong Kong, October, Hong Kong  
 1997 Convener, Cancer Symposia, 110th Anniversary Scientific Congress, University of Hong Kong, October, Hong Kong  
 1999 - 2000 Member, Scientific Committee, Hong Kong International Cancer Congress, Hong Kong, December 2000  
 2000 Organizing member, Delegate of Center for the Study of Liver Disease of HKU to Beijing and Shanghai Universities and Institutes with 5 symposia held.  
 2000 Member, Organizing Committee, Liver Diseases in the New Millennium (Fourth Shanghai International Symposium on Liver Cancer and Hepatitis), September, Shanghai  
 2000 - 2002 Member, Organizing Committee, Scientific Meeting, Centre for the Study of Liver Disease, HKU, February 2001 and 2002  
 2002 - Core member, Scientific Committee, Hong Kong International Cancer Congress  
 2000 - 2002 Organizer, Croucher Advanced Study Institute on 'Molecular Genetics in Cancer Research', January 2001 and January 2002  
 2002 - 2003 Co-Director, Croucher Advanced Study Institute on 'Molecular science of liver diseases: Linking basic science to clinical application', January 2003  
 2003 - 2004 Member, Organizing Committee, 4th International Meeting of Hepatocellular Carcinoma: Eastern and Western experiences (The 3<sup>rd</sup> meeting was held in Italy)  
 2003 - 2004 Director, Scientific Committee, Hong Kong International Cancer Congress 2004

- 2003 - 2006 Member, Core Scientific Committee, Hong Kong International Cancer Congress
- 2004 - 2005 Director, Croucher Advanced Study Institute on 'Molecular genetics and cell signaling in cancers', January 2005 and April 2006
- 2006 – 2008 Director, Croucher Advanced Study Institute on 'Molecular genetics and cell signaling in cancer and cancer metastasis', January 2007 and November 2008

**E. Liver Transplantation**

- 1991 - Present Chief Pathologist responsible for liver transplantation pathology service at Queen Mary Hospital
- 1998 - Present Consultations from Universities in Mainland China for liver transplantation pathology diagnosis
- 2002 Providing training in diagnostic pathology to Senior Pathology Scholar (Dr. Lihua Zhang) Nanjing, Mainland China
- 2004 Providing training in diagnostic pathology to Consultant Pathologist (Prof. Nancy Khin) from Myamir, Burma

<b>5. RESEARCH GRANTS AND AWARDS</b>
--------------------------------------

**External grant from United Kingdom - Association for International Cancer Research (AICR)**

2003 ‘Characterization of novel tumour suppressor genes, DLC1 and DLC2 genes, in liver cancer’ (2003 - 2006) (Principal investigator) £112,500 (~HK\$ 1,693,000)

**Grant from Innovation and Technology Commission (Hong Kong SAR Government) for State Key Laboratory for Liver Research**

2010 Director, HK\$ 2,000,000 per year for 5 years (2010-2015); HK\$5,000,000 per year since 2013

**Research Grants Council (RGC)**

***RGC – Collaborative Research Fund***

2007 ‘Molecular pathology of liver cancer – a multidisciplinary study’ (2007-2010) (PI)  
HK\$ 6,400,000

2010 ‘Molecular pathology of liver cancer – a multidisciplinary study’ (2010-2103) (PI)  
HK\$ 8,100,000 (HK\$9,320,000 if including 15% overhead to HKU)

***RGC – General Research Fund***

2000 ‘Detection of genetic alterations on chromosome 8 in liver cancer by high-throughput fluorescent in-situ hybridization on tissue microarrays and by deletion mapping’ (2000-2002) (PI) HK\$ 763,200

2001 ‘Identification and characterization of DLC-2, a candidate tumour suppressor gene on 13q frequently deleted in liver cancer’ (2001-2004) (PI) HK\$ 954,000

2002 ‘Dysregulation of NF-κB signaling in liver cancer’ (2002-2005) (PI) HK\$ 1,440,000

2002 ‘Functional characterization of a novel liver-enriched transcription factor of the bZIP family’ (2002-2005) (Co-I) HK\$ 1,786,000

2002 ‘Functional conditioning of dendritic cells for DC-based tumor vaccine’ (2002-2005) (Co-I)  
HK\$ 876,000

2003 ‘Deciphering dysregulation of mitotic checkpoint control in liver cancer’ (2003-2006) (PI)  
HK\$ 1,653,000

2003 ‘Characterization of the granulin/epithelin precursor gene in liver cancer’ (2003-2006) (Co-I)  
HK\$ 1,074,000

2004 ‘Functional characterization of DLC1 gene, a novel tumour suppressor gene frequently deleted in liver cancer’ (2004-2007) (PI) HK\$ 1,986,880

2004 ‘Roles and regulation of group II p21-activated protein kinases - implications in cancer metastasis’ (2004-2006) (Co-I) HK\$ 939,968

2005 ‘Roles of p21-activated protein kinase (Pak) 1 in the pathogenesis of liver cancer’ (2005-2008) (Co-I) HK\$ 1,271,914

2006 ‘Significance of LRP6 coreceptor upregulation in the aberrant activation of Wnt signaling in liver cancer’ (2007-2009) (PI) HK\$ 1,830,500

2006 ‘Characterization of tensin2, the binding partner of DLC1 tumor suppressor in liver cancer’ (2007-2009) (Co-I) HK\$ 932,500

2006 ‘GEP as a novel molecular target for liver cancer therapy’ (2007-2008) (Co-I) HK\$ 654,500

2007 ‘Nucleocytoplasmic shuttling mechanism of DLC1 tumor suppressor in liver cancer (2008-2010) (Co-I) HK\$ 1,388,110

2007 ‘Functional characterization of a putative tumor suppressor, AMP-activated protein kinase, in liver cancer’ (2008-2010) (Co-I) HK\$ 1,085,729

2008 ‘Role of mitotic checkpoint gene MAD1 (mitotic arrest deficient 1) in liver cancer’ (2009-2011) (PI) HK\$ 1,020,047

2008 ‘Roles of histone methyltransferases SUV39H1 and SUV39H2 in liver cancer’ (2009-2011) (Co-I) HK\$ 897,578

2010 ‘Significance of cten dysregulation in hepatocarcinogenesis and cancer metastasis’ (2011-2013) (PI) HK\$ 1,032,000

- 2011 'Significance of RhoE dysregulation in liver cancer and metastasis' (2012-2014)  
(PI) HK\$ 1,605,995
- 2013 'The role of Igr5 in liver cancer' (2013-2016)  
(PI) HK\$ 952,636
- 2013 'Role of lysyl oxidase-like 2 (LOXL2) in the progression and metastasis of liver cancer' (2013-2015) (Co-I) HK\$779,429

**RGC - National Natural Science Foundation of China (NSFC) Joint Research Grant**

- 2002 'Characterization of novel genes in liver cancer' (2003-2005) (PI) HK\$ 799,126
- 2006 'Characterization of regulatory molecules of Wnt/ $\beta$ -catenin signaling in liver cancer' (2007-2009) (PI) HK\$ 730,700

**Health and Medical Research Fund, The Hong Kong SAR Government (previously the Research Fund for the Control of Infectious Diseases (RFCID))**

- 2006 'Characterization of the roles of hepatitis B virus X protein in liver cancer' (2006-2008) (PI)  
HK\$ 800,000
- 2012 'Dissecting the gender disparity of hepatocellular carcinoma: Roles of HBV X protein and androgen receptor' (2013-2014) (PI) HK\$ 604,000
- 2013 'Statistical method to identify risk genes of complex diseases based on functional gene sets and networks, with a genetic data mining application to hepatocellular carcinoma' (2013-2015) (Co-I) HK\$ 999,990
- 2013 'Hepatitis B virus infection promotes hepatocellular carcinoma through HIF-1 $\alpha$ /LOXL2 pathway' (2013-2015)  
(Co-I) HK\$ 900,000
- 2013 'Analysis of hepatitis B virus genomic integration and characterization of its role in hepatocarcinogenesis' (2013-2015) (Co-I) HK\$1,000,000

**SK Yee Medical Research Fund**

- 2012 'Medical research on liver diseases for patients' betterment - A proposal from the State Key Laboratory for Liver Research' (2012-2015) (PI)  
HK\$ 5,000,000-

**HKU University Development Fund to State Key Laboratory for Liver Research**

- 2011 HK\$ 5,000,000- for 3 years (2011-2014) (PI)

**Research Collaborative Fund from Pfizer Inc.**

- 2010 Liver cancer research (2010 Jan - 2012 Dec) (PI) HK\$ 8,294,000
- 2011 Characterization of DKK1 as a potential antibody target for HCC (2011-2013) (PI) HK\$ 156,000
- 2013 New target identification or validation and precision medicine patient stratification in HCC (Aug 2013 - Aug 2015) (PI) HK\$1,317,647

**Innovation and Technology Fund, The Government of Hong Kong**

- 2003 Innovation and Technology Support Program  
'Development of novel nucleic acid therapeutics for viral infection and cancer' (2003-2005)  
(Deputy Project Coordinator) HK\$ 2,313,472
- 2011 Innovation and Technology Support Program  
'The use of anti-DKK1 (anti-Dickkopf-1) monoclonal antibody for treatment of liver cancer'  
(2011-2012) (Project Coordinator) HK\$ 999,948
- 2012 Innovation and Technology Support Program  
'Therapeutic monoclonal antibody targeting of CD47 in liver cancer' (2012-2013) (Co-I)  
HK\$1,000,000

**Michael Kadoorie Funded Research in Cancer Genetics (on competitive basis)**

- 2004 'Genome-wide methylation screening in search for novel tumour suppressor genes in liver cancer' (2004-2007) (PI) HK\$ 1,515,371
- 2004 'Characterization of DLC1 gene, a novel tumour suppressor gene frequently deleted in liver cancer' (2004-2007) (PI) HK\$ 1,510,371

**The Hong Kong Thalassemia Foundation**

- 2000 A randomized controlled study on the safety and efficacy of the combined use of oral chelator (L1, 1,2-dimethyl-3-hydroxypyrid-4-ones) and subcutaneous desferrioxamine (desferal) compared to sole use of subcutaneous desferrioxamine in poorly and well chelated transfusion-dependent thalassemia patients (2000-2003) (Co-I) HK\$ 1,200,000

**Croucher Foundation Research Grant**

- 1991 Study of DNA ploidy and tumour suppressor genes and their significance in relation to prognosis and causation of hepatocellular carcinoma (1991) (PI) HK\$ 493,000

**Croucher Foundation Advanced Study Institute**

- 2001 'Croucher Advanced Study Institute on 'Molecular genetic basis of cancer', held in Jan 2001; Awarded HK\$ 590,000 (Organizer)
- 2002 'Molecular science of liver diseases: Linking basic science to clinical application' held in Jan 2003; Awarded HK\$ 531,000 (Co-Director)
- 2004 'Molecular genetics and cell signaling in cancers' held in Jan 2005 and Apr 2006; Awarded HK\$ 600,000 (Director)
- 2006 'Molecular genetics and cell signaling in cancers and cancer metastasis' held in Jan 2007; Awarded HK\$ 600,000 (Director)

**Croucher Summer Course**

- 2012 Croucher Summer Courses in Cancer Biology, in 2013, 2015 and 2017, from Croucher Foundation; Awarded HK\$ 1,800,000 (As Director)

**The University of Hong Kong**

**University Research Committee (HKU)**

- 2003 Postdoctoral fellow for the research area on 'RNA interference in cancers' ~HK\$ 600,000 over 3 years
- 2004 Research Assistant Professor for the research area on 'Functional characterization of novel genes in liver cancer' ~HK\$ 900,000 over 2 years
- 2004 Postdoctoral fellow for the research area on 'Strategic identification and characterization of novel genes in liver cancer' ~HK\$ 700,000 over 3 years
- 2005 Postdoctoral fellow for the research area on 'Functional genomics of novel and important genes in liver cancer using mouse models' ~HK\$ 700,000 over 3 years
- 2007 Postdoctoral fellow for the research area on 'Molecular pathology of liver cancer – a multidisciplinary study' ~HK\$ 700,000 over 3 years
- 2007 Research Assistant Professor for the research area on 'Hepatocellular carcinoma' ~HK\$ 3.48 million over 6 years
- 2008 Postdoctoral fellow for the research area on 'Identification of specific cancer stem cells for liver cancer therapy' ~HK\$ 700,000 over 3 years
- 2009 Postdoctoral fellow for the research area on 'Study of important cell signaling pathway in liver cancer for Identification of potential biomarkers' ~HK\$ 700,000 over 3 years

**University CRCG grants**

1. Multiple drug resistance gene expression in liver and nasopharyngeal cancers (1995) (PI) HK\$ 106,000
2. An in-vitro study of chemotherapy sensitivity in relation to apoptosis in cancer (1996) (PI) HK\$ 165,000
3. A study of vascular endothelial growth factor and related angiogenic factors in hepatocellular carcinoma - their relation to tumour progression and prognosis (1997) (PI) HK\$ 115,000
4. Microsatellite instability in relation to carcinogenesis and prognosis in liver cancer (1998) (PI) HK\$ 86,000
5. Characterization of a new gene DLC1 (frequently deleted in liver cancer gene) in hepatocellular carcinoma (1999) (PI) HK\$ 108,000
6. Genetic progression and divergence in hepatocellular carcinoma (2000) (PI) HK\$ 95,000
7. Chimerism in transplanted livers (2002) (PI) HK\$ 87,900
8. Characterization of T-cadherin in hepatocellular carcinoma (2003) (PI) HK\$58,000
9. Characterization of the Dishevelled gene in Wnt/beta-catenin signaling in liver cancer (2005) (PI) HK\$120,000
10. Characterization of tensin2, the binding partner of DLC1 tumour suppressor in liver cancer (2005) (Co-I) HK\$120,000
11. LRP6 coreceptor upregulation in liver cancer (2006) (PI) HK\$120,000
12. Functional characterization of DLC2 in suppression of cancer cell growth and tumorigenicity in liver cancer (2006) (Co-I) HK\$ 80,000
13. The role of Frizzled-7, receptor of the WNT/ $\beta$ -catenin signalling pathway, in hepatocellular carcinoma: Implications in tumorigenesis and metastasis (2006) (Co-I) HK\$ 80,000
14. Functional characterization of the mitotic checkpoint protein MAD1 in liver cancer (2007) (PI) HK\$ 40,000
15. The role of hepatitis B virus X protein in dysfunction of chromosomal segregation machinery via interaction with BUBR1 in hepatocellular carcinoma (2007) (Co-I) HK\$ 58,840
16. Dissecting the PI3K/Akt signaling network and its clinicopathological significance in liver cancer (2008) (PI) HK\$ 80,000
17. Roles of histone methyltransferases SUV39H1 and SUV39H2 in liver cancer (2008) (Co-I) HK\$ 120,000
18. Functional implications of Akt phosphorylation of DLC1 tumor suppressor in liver cancer (2008) (Co-I) HK\$ 106,000
19. The novel role of a splice variant of carboxypeptidase E (CPE-deltaN) in HCC metastasis (2008) (Co-I) HK\$ 120,000
20. Development of diagnostic use of a novel phospho-antibody in liver malignancy (2008) (Co-I) HK\$ 100,000
21. Study of the role of the tumor suppressor phosphatase and tensin homolog (PTEN) in liver cancer and metastasis (2009) (PI) HK\$ 70,000
22. Significance and transcriptional upregulation of caveolin-1 by PPAR $\gamma$  in liver cancer metastasis (2009) (Co-I) HK\$ 70,000
23. Functional and pathological implications of EZH2 in human HCC (2009) (Co-I) HK\$ 70,000
24. Significance of cten dysregulation in hepatocarcinogenesis and cancer metastasis (2010) (PI) HK\$100,000
25. Dissection of DLC1/Rho/ROCK2 signaling pathway in liver cancer (2011) (PI) HK\$ 51,000
26. Role of hypoxia-inducible miR-210 in liver cancer (2012) (PI) HK\$84,100

<b>6. TEACHING AND EXAMINERSHIP</b>
-------------------------------------

**TEACHING****□ Postgraduate teaching and supervision****A. Graduate theses supervised (The University of Hong Kong)**

Six PhD, 6 MPhil and 3 MMedSc students (with me as Principal Supervisor) and 7 PhD and 7 MPhil students (with me as Co-Supervisor) graduated

**As Principal Supervisor:**

1997 - 2000	‘Targeted gene delivery using a receptor-mediated gene transfer system and chemosensitivity in hepatocellular carcinoma’ (MPhil), KW Lee (Now as Assistant Professor at HKU)
1997 - 2000	‘Significance of cell cycle regulators in human hepatocellular carcinoma and gene expression induced by cisplatin in hepatoma cell lines’ (PhD), Dr. LF Qin, M.D. (Now a Postdoctoral Fellow at Baylor Medical College, U.S.A.)
1997 - 1999	‘Correlation of microsatellite instability and loss of heterozygosity with prognosis in hepatocellular carcinoma’ (MMedSc.), Matthew Ho (Now a Hospital Medical Technologist)
1999 - 2000	‘A study of mutation and expression of $\beta$ -catenin in hepatocellular carcinoma’ (MMedSc.), CM Wong (Now an Assistant Professor at HKU)
2000 - 2002	‘Molecular alterations on chromosome 8 in hepatocellular carcinoma’ (MPhil), KL Chan (Now a Postdoctoral Fellow at Oxford University)
2001 - 2003	‘Dysregulation of NF- $\kappa$ B signaling in hepatocellular carcinoma’ (MPhil), CF Chan (Now a bioscience firm manager in Hong Kong)
2001 - 2003	‘Novel candidate tumour suppressor genes, DLC1 and DLC2, in hepatocellular carcinoma’ (PhD), CM Wong (Now an Assistant Professor at HKU)
2002 - 2006	‘Characterization of mitotic checkpoint proteins, MAD1 and MAD2, in hepatocellular carcinoma’ (PhD), Karen MF Sze (Now a Postdoctoral Fellow at HKU)
2003 - 2005	‘Identification and characterization of a novel tumor suppressor gene, Deleted in Liver Cancer 2, (DLC2)’, (PhD), Thomas HY Leung (Now a Postdoctoral Fellow at HKU)
2004 - 2007	‘Molecular studies of hepatocellular carcinoma’ (PhD), Edmund KK Tung (Now a Scientific Officer at Queen Mary Hospital of the Hospital Authority)
2005 - 2007	‘mTOR signaling in hepatocellular carcinoma’ (MPhil), ICF Hui (Now a Medical Officer at Queen Mary Hospital of the Hospital Authority)
2005 - 2008	‘Functional studies of DLC1 (deleted in liver cancer) gene in hepatocellular carcinoma’ (PhD), Carmen CL Wong (Now a Research Assistant Professor at HKU; was a Croucher Postdoctoral Fellow at Johns Hopkins University)
2006 - 2008	‘Significance of LRP6 coreceptor upregulation in the aberrant activation of Wnt signaling in hepatocellular carcinoma’ (MPhil), Betty YC Wong
2006 - 2008	‘Study of the role of the tumor suppressor phosphatase and tensin homolog (PTEN) in hepatocellular carcinoma’ (MPhil), Lai-Ting Wong
2010 - 2013	‘Roles of hypoxia-inducible microRNA-210 in hepatocellular carcinoma’ (PhD), Alan Kai (Now a Postdoctoral Fellow at HKU)
2009 – 2013	‘Study of the roles of RhoE in human hepatocellular carcinoma’ (PhD), Wei Ma (Now a Postdoctoral Fellow at HKU)
2009 – 2013	‘Study of the roles of Dishevelled-3 in stemness and cell migration in hepatocellular carcinoma’ (PhD), Yu-Man Tsui (Now a Postdoctoral Fellow at HKU)

**As Co-supervisor:**

1995 - 1998	‘Prospective evaluation of Pringle maneuver in hepatectomy for liver tumours’ (PhD), Dr. Kwan Man, MD. (Now an Associate Professor at HKU)
-------------	--

- 1995 - 1998 'Mechanism of spontaneous rupture of hepatocellular carcinoma' (PhD), Dr. Li-xin Zhu, MD (Co-supervisor) (Now a Professor at Zhe-Jiang University, China)
- 2003 - 2005 'Functional characterization of DLC2 gene', (PhD), David C.H. Ng (Now a Postdoctoral Fellow at HKU)
- 2004 - 2008 'Characterization of binding partners of DLC1 tumour suppressor gene in hepatocellular carcinoma' (PhD), LK Chan (Now a Postdoctoral Fellow at HKU)
- 2004 - 2006 'PAK in hepatocellular carcinoma', (MPhil), Helen HT Xu (Now a Research staff in Biopharmaceutical company in China)
- 2004 - 2005 'Epigenetic regulation of gene expression of cystatin 6, CST6, in hepatocellular carcinoma', (MMedSc), Marcella KL Ma (Now a Research Assistant in UK)
- 2005 - 2007 'AMPK cell signaling in hepatocellular carcinoma', (MPhil), Michael Liu, now a Research Assistant at HKU)
- 2005 - 2008 'Molecular regulations of Deleted in Liver Cancer (DLC) protein family', (PhD), Frankie CF Ko (Now a Now a Postdoctoral Fellow at HKU)
- 2006 - 2010 'bZIP transcription factors in hepatic physiology and pathology', (PhD), CP Chan
- 2007 - 2011 'Epigenetic role and functions of Enhancer of Zeste Homolog 2 in hepatocellular carcinoma', (PhD), Sandy Leung-Kuen Au (Now a Postdoctoral Fellow at U of Toronto)
- 2008 - 2010 'Identification of liver tumour-initiating cells using a chemoresistant animal model' (MPhil), Antonia Castilho (Now an MBChB student at CUHK)
- 2009 - 2011 'Identification of CD47 as a novel therapeutic target for hepatocellular carcinoma', (MPhil), Vincent Chi-Ho Cheung (Now an MBChB student at CUHK)
- 2009 - 2011 'Oncogenic role of integrin-linked kinase in hepatocellular carcinoma', (MPhil), Jenny Chan
- 2009 - 2011 'Epigenetic dysregulation of microRNA-9 (miR-9) in hepatocellular carcinoma', (MPhil) Aegean HK Tam.
- 2010 - 2012 'Role of hypoxia-induced upregulation of caveolin-1 in hepatocellular carcinoma', (MPhil), Sivia Yuen-Sze Wong ((Now an MBBS student at HKU)

**Awards to postgraduate students** (as principal supervisor if not indicated otherwise)

- 1999 **Winner of Young Investigators' Award** to Lee TWK, for the paper 'In-vitro and in-vivo efficiency of gene delivery using a novel receptor-mediated gene transfer system in hepatocellular carcinoma', in 6<sup>th</sup> Hong Kong International Cancer Congress, Hong Kong
- 2000 **Winner of the best paper award runners-up**, Lee TWK, for the paper 'Gene delivery using a novel receptor-mediated gene transfer system in hepatocellular carcinoma', in 17th Meeting of International Academy of Tumor Marker Oncology, Hong Kong
- 2000 **Winner of Young Investigators' Award and Winner of Journal of Hepatology and Gastroenterology Young Investigator Award**, TWK Lee, in 11<sup>th</sup> Asian Pacific Congress of Gastroenterology and 8<sup>th</sup> Asian Pacific Congress of Digestive Endoscopy
- 2002 **Winner of the Young Investigator Award**, 9<sup>th</sup> Hong Kong International Congress of Cancer and 18<sup>th</sup> World Congress of the International Society for Digestive Surgery, 2002 to Chun-Ming Wong, PhD student
- 2003 **Croucher Scholarship** to Kok-Lung Chan, MPhil graduate
- 2003 **Sir Edward Youde Fellowship** to Anthony Chun-Fung Chan, MPhil student
- 2003 **Li Ka Shing prize for the best MPhil thesis** to Kin-Wah Lee, MPhil graduate, on the thesis entitled 'Targeted gene delivery using a receptor-mediated gene transfer system and chemosensitivity in hepatocellular carcinoma'
- 2004 **AACR-ITO EN Scholar-in-Training Award** to Leung Ho Yin, Thomas, PhD student, on presentation entitled 'Characterization of novel putative tumor suppressor gene, *DLC2* (deleted in liver cancer 2), in hepatocellular carcinoma'
- 2004 **Young Investigator Award**, 4th International Meeting of Hepatocellular Carcinoma: Eastern and

- Western experiences, to Leung Ho Yin, Thomas, PhD student
- 2006 **Best Presentation Award**, Departmental Postgraduate Seminar, HKU, to Carmen Wong, PhD student
- 2006 **Best Presentation Award**, Departmental Postgraduate Seminar, HKU, to Michael Liu, MPhil student (as Co-supervisor)
- 2006 **Best PhD Presentation Award in Cancer**, 11<sup>th</sup> Research Postgraduate Symposium, LKS Faculty of Medicine, HKU, December to Carmen Wong, PhD student
- 2006 **Best Poster Presentation Award**, 11<sup>th</sup> Research Postgraduate Symposium, LKS Faculty of Medicine, HKU, December to Michael Liu, MPhil student (as Co-supervisor)
- 2007 **AACR-ITO EN Scholar-in-Training Award** to Edmund KK Tung, PhD student
- 2007 **Young Investigator Award**, to Carmen CL Wong, PhD student, by the Hong Kong International Cancer Congress
- 2007 **Best PhD Presentation Award in Cancer**, 12<sup>th</sup> Research Postgraduate Symposium, LKS Faculty of Medicine, HKU, December to Lo-Kong Chan, PhD student (as Co-supervisor)
- 2008 **Young Investigator Award**, to Ms Carmen CL Wong, PhD student, in the Hong Kong-Shanghai International Liver Congress 2008
- 2008 **Mary Sun Medical Scholarship** 2007-2008 to Ms Carmen CL Wong, PhD student
- 2008 **Hong Kong International Cancer Congress** 2008 Young Investigator Award to Ms Edith Tse, PhD student (as Co-supervisor)
- 2008 **Postgraduate Research Symposium 2008** Overall best PhD paper to Carmen C.L. Wong
- 2009 **Croucher Postdoctoral Fellowship** for overseas postdoctoral fellow training to Carmen C.L. Wong, PhD student
- 2009 **Dr. KP Stephen Chang Gold Medal 2008-2009** to Carmen C.L. Wong, PhD student
- 2009 **Hong Kong Young Scientist Award (Life Science)**, Hong Kong Institution of Science to Carmen C.L. Wong, PhD student
- 2009 **Hong Kong International Cancer Congress** 2009 Young Investigator Award to Sandy LK Au, PhD student (as Co-supervisor)
- 2010 **Hong Kong International Cancer Congress** 2010 Young Investigator Award to Vincent Chi-Ho Cheung, MPhil student (as Co-supervisor)
- 2010 **Li Ka Shing Prize for the Best PhD Thesis** to Carmen C.L. Wong, PhD student
- 2010 **Best PhD Presentation Prize, Research Postgraduate Symposium**, HKU Medical Faculty to Sandy L.K. Au, PhD student
- 2011 **Outstanding Research Postgraduate Student award**, the Graduate School, HKU, to Antonia Genevieve Castilho, MPhil student
- 2011 **Best Presentation Award**, Departmental Postgraduate Seminar, HKU, to Wei Ma, PhD student
- 2011 **Best PhD poster**, Postgraduate Research Symposium 2011 to Alan Kai, PhD student
- 2012 **Best Presentation Award**, Departmental Postgraduate Seminar, HKU, to Alan Kai, PhD student
- 2012 **Outstanding Research Postgraduate Student award**, the Graduate School, HKU, to Vincent CH Cheung, MPhil student
- 2012 **Best PhD poster**, Postgraduate Research Symposium 2011 to Eunice Lau, PhD student

**B. Teaching in Postgraduate Courses (The University of Hong Kong)**

- 2000 - Lectures in Faculty-based Core and Specialized Modules in PhD/MPhil/MMedSc courses
- 2004 - Coordinator, Cytogenetics and Molecular Genetics of Cancer

□ **Undergraduate teaching**

**A. Undergraduate (Medical) (The University of Hong Kong)**

*New MBBS problem-based learning (PBL) curriculum:*

- 1998 - Case coordinator and panel discussant, clinicopathological conferences, year IV & V
- 1998 - Department coordinator in System-based Module, new MBBS curriculum
- 1998 - Lecturer and tutor (problem-based learning and small group teaching) in Pathology, new MBBS curriculum
- 2001 - Member, Problem-based Learning Planning Group, Faculty of Medicine
- 2001 - PBL Education Tutor

*Old MBBS curriculum:*

- 1981 - 1998 Panel discussant, clinicopathological conferences, years IV & V
- 1987 - 1998 Lecturer, integrated teaching sessions, M.B.B.S. year IV
- 1981 - 1999 Lecturer and tutor in Pathology, M.B.B.S. year II and III courses

**B. Undergraduate (BDS, Bachelor of Dental Science) (The University of Hong Kong)**

*New BDS problem-based learning curriculum:*

- 1998 - Coordinator and demonstrator for Practical Sessions
- 1999 - Tutor (problem-based learning), new BDS curriculum
- 1999 - 2004 Discipline consultant, new BDS curriculum

*Old BDS curriculum:*

- 1982 - 1999 Lecturer and Tutor, B.D.S. year II Pathology course
- 1996 - 2000 Principal Lecturer, B.D.S. year IV Applied Histopathology Course
- 1996 - 1999 Course Director, B.D.S. year II Pathology course
- 1996 - 2000 Course Director, B.D.S. year IV Applied Histopathology Course

**C. Undergraduate (Bachelor of Chinese Medicine) (The University of Hong Kong)**

- 2003 - Lecturer and Practical demonstrator and Tutor

□ **Teaching Innovation and Curriculum Development**

- 1997 Visit to the School of Dentistry and Medicine, University of California, San Francisco, with special emphasis on teaching of dental pathology
- 1996 Introduced clinicopathological conference for dental undergraduates in B.D.S. year IV Applied Oral Pathology Course
- 1996 - Member, Departmental Curriculum Committee
- 1997 - 2004 Discipline Coordinator for Pathology, new problem-based learning curriculum, Faculty of Dentistry
- 2001 - Member, Problem-based Learning Planning Group, Faculty of Medicine
- 1997 - Member, System-based Blocks Planning Group, new problem-based learning MBBS Curriculum, Faculty of Medicine
- 2002 - Problem-based learning Tutor Educator, Faculty of Medicine

**EXAMINERSHIP**

**A. International Professional Examination**

- 1999 - 2004 Examiner, Royal Australasian College of Dental Surgeons

**B. Hong Kong College of Pathologists**

- 2008 - 2012 Chief Examiner in Anatomic Pathology, the Hong Kong College of Pathologists

**C. Examiner of doctorate or postgraduate theses**

- 1998 MPhil thesis 'Meniscectomy and autogenous graft reconstruction of the Rhesus monkey temporomandibular joint articular disc' by Dr. A Tong, B.D.S., HKU
- 1998 PhD thesis 'Mechanisms of the adverse actions of cigarette smoking on gastric ulcer formation and its healing in the rat' by Dr. L Ma, M.D, HKU
- 1999 Committee member, Candidacy Examination for Ph.D student, Mr. SC Wong, Hong Kong University of Science and Technology
- 2000 PhD thesis 'Significance of cell cycle regulators in human hepatocellular carcinoma and gene expression induced by cisplatin in hepatoma cell lines' by Dr. LF Qin, HKU
- 2000 MPhil thesis 'Targeted gene delivery using a receptor-mediated gene transfer system and chemosensitivity in hepatocellular carcinoma' by Mr. KW Lee, HKU
- 2001 MPhil thesis 'p15 and p16 genes in head and neck carcinoma' by Mr. WL Man, HKU
- 2002 MPhil thesis 'Molecular alterations on chromosome 8 in hepatocellular carcinoma' by Mr. KL Chan, HKU
- 2002 PhD thesis 'The role of cyclooxygenase-2 in chronic hepatitis B' by Mr. SL Cheng, Chinese University of Hong Kong
- 2002 PhD thesis 'The expression and clinical applications of Wnt-signaling molecules in breast and colorectal cancers' by Mr. SC Wong, Hong Kong University of Science and Technology
- 2003 MPhil thesis 'Significance of thrombospondin 1 (THBS1) in hepatocellular carcinoma' by Mr. KK Chung, HKU
- 2003 MPhil thesis 'Dysregulation of NF- $\kappa$ B signaling in hepatocellular carcinoma' by Mr. CF Chan, HKU
- 2003 PhD thesis of 'The role of precore and core promoter mutations in Chinese patients with chronic hepatitis B' by Mr. HJ Yuan, HKU
- 2003 M.D. thesis of 'Chronic hepatitis C infection: diagnosis, fibrosis progression and interferon therapy' by Dr. CK Hui, HKU
- 2004 PhD thesis of 'Molecular cytogenetic, epigenetic and tissue dynamic study of gestational trophoblastic disease' by Wei-Cheng Xue, HKU

Chairperson of Oral Examination:

- 1999 MPhil thesis 'Expression of gap-junctional connexin 31 in rat testis' by Ms. WY Mok, HKU
- 2000 MPhil thesis 'A study of molecular and cell biology of prostate tumorigenesis in cell culture' by Mr. MT Ling, HKU
- 2000 MPhil thesis 'DNA microsatellite co-segregation of polycystic kidney disease 1 (PKD1) gene in autosomal dominant polycystic kidney disease (ADPKD) families and cell culture models for ADPKD' by Mr. Forrest CF Yau, HKU
- 2001 PhD thesis 'A study of genomic imprinting and DNA methylation in gynecological cancer' by Ms. CL Chen, HKU
- 2004 PhD thesis 'Local and systemic effects of hepatic radiofrequency ablation in animal models' by Dr. Kelvin KC Ng, HKU

**D. Undergraduate**

**New problem-based learning curriculum**

- 1998 - Examiner, MBBS year I & II
- 1999 - Examiner, BDS II examination
- 2000 Chief Examiner, MBBS II examination

**Old curriculum**

- 1996 - 1999 Chief Examiner, B.D.S. II examination in Pathology
- 1996 - 2001 Examiner, B.D.S. Final Examination

## 7. PROFESSIONAL STANDING

### **Speaker at International Conferences and World-famous Institutions**

To name some examples:

- University of California, San Francisco
- Institute of Liver Studies, King's College Hospital, London
- Pasteur Institute, Paris, 2003
- Inserm U434, Institut de génétique moléculaire, Paris, 2003
- Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, March 2004
- Asian Pacific Association of the Study of Liver Disease, New Deli, India, 2004
- World Congress of Gastroenterology 2005 Meeting 'Global Goals in Gastroenterology: Expanding Horizons for the 21st Century', Montréal, Canada, 2005
- 18<sup>th</sup> Asia Pacific Cancer Conference, Seoul, Korea, 2005
- University of Toronto, Canada, 2006
- Laboratory of Experimental Carcinogenesis, National Institute of Health, Bethesda, 2007
- American Association for Cancer Research Annual Meeting 2008, San Diego, USA
- Consultants' Meeting on development of guidelines for the palliative management of common cancers using radiotherapy in limited resource settings: liver cancer, IAEA, United Nations, Vienna 2008
- International Liver Cancer Association 7th Annual Conference - ILCA-EASL-NCI-AASLD Workshop on Molecular Classification and Biomarkers in HCC, Washington, DC, USA, 2013

### **Member of International Study Groups**

- Laennec Society on Liver Pathology (an International liver pathology group with members from >10 countries)
- International Cooperative Study Group on Hepatocellular Carcinoma (The University of Texas M.D. Anderson Cancer Center, Mayo Clinic, Hôpital Beaujon, Paris, and University of Hong Kong Medical Center)

### **Organizer of International Conferences**

2001	Liver Diseases in the New Millennium (Fourth Shanghai International Symposium on Liver Cancer and Hepatitis), September 2001, Shanghai
2003-2004	Hong Kong International Cancer Congress, November 2004, Hong Kong
2003-2004	4th International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences (The 3 <sup>rd</sup> meeting held in Italy), December 2004
2004- Present	Hong Kong International Cancer Congress, Hong Kong

### **Area of Excellence, University of Hong Kong**

1998 -	Member, Executive Committee, Centre for the Study of Liver Disease, Area of Distinction
--------	---

### **Croucher Advanced Study Institute, Hong Kong**

2000 - 2001	Organizer, Croucher Advanced Study Institute on 'Molecular genetic basis of cancer', January 2001
2002 - 2003	Co-Director, Croucher Advanced Study Institute on 'Molecular science of liver diseases: Linking basic science to clinical application', January 2003
2004 - 2005	Director, Croucher Advanced Study Institute on 'Molecular genetics and cell signaling in cancers', January 2005 and April 2006
2007 - 2008	Director, Croucher Advanced Study Institute on 'Molecular genetics and cell signaling in cancers and cancer metastasis', January 2007 and November 2008

### **Croucher Summer Course in Cancer Biology, Hong Kong**

2013 - 2017	Director, Croucher Summer Course in Cancer Biology, 2013, 2015 & 2017
-------------	---

<b>8. ADMINISTRATION AND SERVICES</b>
---------------------------------------

**A. Hong Kong**

2013 -	Member, Clinical Medicine Panel, Research Assessment Exercise 2014, University Grants Committee
2007 -	Member, Grant Review Board, Research Council, Food and Health Bureau, Government of Hong Kong Special Administrative Region
2006 - 2012	Member, Hong Kong Research Grants Council (Panel of Biology and Medicine)
2007 - 2011	Member, National Natural Science Foundation of China (NSFC)/RGC Joint Selection Committee, Hong Kong Research Grants Council
2007 - 2010	Member, the Nursing Council of Hong Kong (Appointed by the Government of Hong Kong SAR)
2007 - 2012	Member, Accreditation Committee (to accredit Nursing Programs in Hong Kong), the Nursing Council of Hong Kong

**B. Hong Kong College of Pathologists**

1993 - 2005	Member, Subcommittee on Quality Assurance Program in Anatomical Pathology
1994 - Present	Education supervisor, Hong Kong College of Pathologists
1996 - 2005	Member, Subcommittee on Quality Assurance Program
1996 - 2010	Inspector, for accreditation of laboratory training in Anatomical Pathology
2005 - 2007	Chairperson, Specialty Board in Anatomical Pathology
2004 - 2008	Elected Member, College Council
2008.1 – 2012.03	Chief Examiner in Anatomic Pathology

**C. The University of Hong Kong**

2003 - 2006	Member, Committee on Research and Conference Grants for Medicine
2004, 2006, 2012	Ad hoc member, University Research Committee
2005 - 2011	Member, University's Committee on Research and Conference Grants
2007 - 2009	Member, Promotion and Tenure Panel, Faculty of Dentistry
2009 – 2012.6	Member, Promotion and Tenure Panel, Faculty of Science
2008, 2012	Ad hoc member, University Selection and Promotion Committee
2007 - 2008	Member, Task Force of RGC Visit 2008
2009 - 2011	Member, Committee on Research and Conference Grants
2010 - 2014	Member, the Policy Board of Postgraduate Education
2011 -	Head, Department of Pathology

**D. Faculty of Medicine, The University of Hong Kong**

1986 - Present	Member, Board of Faculty of Medicine
1992 - 2000	Member, Selection Committee, HKU Medical Faculty Student Loan Fund
1996 - 1997	Member, Organizing Committee, 110th Anniversary Scientific Congress
1997	Convener, Cancer Symposia, 110th Anniversary Scientific Congress
2001 - Present	Member, Sun Yat Sen Foundation Fund for Academic Exchanges with China
2001 - Present	Member, Problem-based Learning Planning Group, Faculty of Medicine
2003 - Present	Member, Faculty Internal Review Panel for RGC grant applications
2003 - Present	Member, Search Committee for Chair of Pathology
2003 - 2005	Member, Committee on Research and Conference Grants (Research Panel for Medicine)
2004- 2007; 2010-	Member, Faculty Higher Degrees Committee
2003 - Present	Internal reviewer for RGC CERG grant applications
2005 - Present	Member, Faculty Research Committee

2007 - 2013 Assistant Dean (Research)  
 2010 Chairman, Research Taskforce for a Proposal for Central Grant for research in the HKU-Shenzhen Hospital

**E. Faculty of Dentistry, University of Hong Kong**

1997 - 2004 Member, Board of Faculty of Dentistry

**F. Department of Pathology, University of Hong Kong**

1992 - 1999 Coordinator, Quality Assurance Program in Surgical Pathology  
 1992 - 2000 Deputy-in-charge, Surgical Pathology  
 1996 - 2000 Departmental coordinator, interdepartmental Head and Neck Seminars  
 1996 - Coordinator, interdepartmental clinicopathological conference in Oral Pathology  
 1996 - Member, Curriculum Committee  
 Sep - Nov 1999 Acting Head of Department  
 2002 - Member, Convenors' Meeting (core group of Head of Department)  
 2002 - Research Convenor  
 2002 - 2008 Chairperson, Departmental Research Postgraduate Committee

**G. Queen Mary Hospital**

1993 - 1998 Member, Coordinating Committee on Quality Management  
 1994 - 1998 Member, Committee on Research, QMH Cancer Centre  
 1990 - Key pathologist and pathologist-in-charge, Pioneer liver transplantation team at Queen Mary Hospital

**H. Hospital Authority**

1995 - 2003 Member, Laboratory Workload Statistics Subcommittee, Anatomic Pathology division

<b>CLINICAL SERVICE</b>
-------------------------

**A. Queen Mary Hospital**

1986 - Team Supervisors in Surgical Pathology, Autopsy, and Cytology services  
 1991 - Pathologist-in-charge and Key Pathologist, Liver Transplantation Service (Pioneer liver transplantation in Hong Kong since 1991)  
 1996 - Honorary Consultant, Department of Pathology, Queen Mary Hospital, Hospital Authority, Hong Kong  
 1996 - 2005 Pathologist-in-charge, Oral Pathology Clinicopathological Meeting  
 1996 - Pathologist providing private, large-scale cytology screening service

**B. China**

1997 - Providing liver pathology and liver transplantation pathology consultation service for Mainland China and Asia (the Philippines)  
 1997 - Providing liver transplantation pathology training for pathologists from Mainland China and Asia

January 2014